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ANNEX I 
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ANNEX II 
 
Table of LL-37 and analogues. Green letter refers to hydrophilic amino acids; Black and underlined refers to positive charged amino acids; Purple and italics refers to negative charged amino 
acids; Blue corresponds to polar amino acids; Orange refers to special amino acids; Red refers to the modifications done. The names of the analogues are designed with the first two letters of 
the sequence followed by the modified residue with the position within the sequence (red). The pale pink background is the controls synthesized. The blue background corresponds to the 
disruption of the hydrophilic zone by amino acid Ser. The pale orange background refers to where the bench is located in the peptide sequence. Yellow background is the minimum sequence 
needed to obtain biological activity by literature. Bright pink background refers to C-terminal modification by an amide termination. Ac-KS-30; Ac-KS-30-NH2 and KS-30-NH2 have the C-
terminal, N-terminal or both modified by acetylation (brown) or/and amidation (bright pink). aNet charge at pH = 7. 
 
Sequences 
 
ID Name 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Chargea 
LL-37 LL-37 L L G D F F R K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 6 
FK-13 FK-13                 F K R I V Q R I K D F L R         + 4 
KR-12 KR-12                  K R I V Q R I K D F L R         + 4 
RK-31 RK-31       R K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 7 
KS-30 KS-30        K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 6 
KR-20 KR-20                  K R I V Q R I K D F L R N L V P R T E S + 4 
(11) AS-30        A S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 5 
(12) KF-30        K F K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 6 
(13) KSA7-30        K S K E K I A K E F K R I V Q R I K D F L R N L V P R T E S + 6 
(14) KSR8-30        K S K E K I G R E F K R I V Q R I K D F L R N L V P R T E S + 6 
(15) KSG8-30        K S K E K I G G E F K R I V Q R I K D F L R N L V P R T E S + 5 
(16) KS-30- NH2        K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 6 
(17) Ac-KS-30      CH3 CO K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 6 
(18) Ac-KS-30- NH2      CH3 CO K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 6 
(19) KK-31       K K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 7 
  
 
 
 
 
 
 
 
 
Continuation: table of LL-37 and analogues. Green letter refers to hydrophilic amino acids; Black and underlined refers to positive charged amino acids; Purple and italics refers to negative 
charged amino acids; Blue corresponds to polar amino acids; Orange refers to special amino acids; Red refers to the modifications done. The names of the analogues are designed with the 
first two letters of the sequence followed by the modified residue with the position within the sequence (red). The pale pink background is the controls synthesized. The blue background 
corresponds to the disruption of the hydrophilic zone by amino acid Ser. The pale orange background refers to where the bench is located in the peptide sequence. Yellow background is the 
minimum sequence needed to obtain biological activity by literature. Bright pink background refers to C-terminal modification by an amide termination. Ac-KS-30; Ac-KS-30-NH2 and KS-
30-NH2 have the C-terminal, N-terminal or both modified by acetylation (brown) or/and amidation (bright pink). aNet charge at pH = 7. 
 
Sequences 
ID Name 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 Chargea 
(20) KSA3-30        K S A E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 5 
(21) KSF17-30        K S K E K I G K E F K R I V Q R F K D F L R N L V P R T E S + 6 
(22) KS-22        K S K E K I G K E F K R I V Q R I K D F L R         + 6 
(23) KS-26        K S K E K I G K E F K R I V Q R I K D F L R N L V P     + 6 
(24) KSA29-30        K S K E K I G K E F K R I V Q R I K D F L R N L V P R T A S + 7 
(25) KSA9-30        K S K E K I G K A F K R I V Q R I K D F L R N L V P R T E S + 7 
(26) KS-27        K S K E K I G K E F K R I V Q R I K D F L R N L V P R    + 7 
(27) KE-23               K E F K R I V Q R I K D F L R N L V P R T E S + 4 
(28) FF-22                F F K R I V Q R I K D F L R N L V P R T E S + 4 
(29) SK-29         S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 5 
(30) KE-28          K E K I G K E F K R I V Q R I K D F L R N L V P R T E S + 5 
(31) FK-21                 F K R I V Q R I K D F L R N L V P R T E S + 4 
(32) KF-22                K F K R I V Q R I K D F L R N L V P R T E S + 5 
(33) FKG13-13                 F K R I V Q R I K D F L G         + 3 
(34) FKF12G-13                 F K R I V Q R I K D F F G         + 3 
(35) FKN3-13                 F K N I V Q R I K D F L R         + 3 
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1. INTRODUCTION 
1.1. Fungal infections 
Fungi have become a major issue in critically ill patients and, in the latest years, invasive 
fungal infections have risen as one of the major causes of morbidity and mortality for 
immunocompromised patients. [1] Fungi can grow in two forms, i.e. yeast and moulds, and 
appear as either endogenous or exogenous infections (Figure 1). [2,3] 
 
Figure 1. Flow chart representing source and consequences of invasive fungal infections: where they can be 
found, what kind of infections they can develop and the consequences of those infections for 
immunocompromised patients. 
 
Fungal infections are often classified as opportunistic or primary. [4] The main difference 
between those types of infections is that the opportunistic ones take advantage of a weakened 
immune system, while the primary ones can occur in patients with a healthy immune system.  
The most common opportunistic pathogenic fungi are Candida albicans, Aspergillus 
fumigatus and Cryptococcus neoformans among others. [5,6] 
Candida albicans exists as a harmless commensal pathogen in oral cavities as well as in 
gastrointestinal and genitourinary tracts, behaving as normal flora. Although bacteria present 
in those tracts control the growth of Candida in such areas, the use of antibiotics may allow 
fungi to grow unchecked, thus causing the infection. Normally, the balance is restored once 
bacteria grow back and hence the infection usually resolves with no further problems. That 
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would be the case of the typical vaginal candidiasis, of which according to some studies 
almost 75 % of reproductive-age women will be affected at least once in their life. [7] 
Although these superficial infections are quite common and produce no major harm, they may 
become severe in immunocompromised individuals, such as HIV-infected or chemotherapy 
patients, transplant recipients and low birth weight infants. Damage caused by Candida 
albicans infection, generally known as candidiasis, may range from superficial to life-
threating. [8, 9] 
Thus, Candida has become a serious medical problem, specially due to the high level of 
resistance it exhibits against most clinically used antifungals drugs, which has been related to 
its ability to form biofilms. [10] 
 
1.2. Fungal resistance and antifungal drugs 
The World Health Organization recognizes the antifungal resistance as one of the three major 
threats to human health. [11] Basically, emerge of drug-resistance, poor diagnosis and lack of 
effective antifungal drugs are the main factors for the high mortality and morbidity. [12] 
Developing effective antifungal drugs and therapies is quite challenging, as fungi are 
eukaryotes. They share many similarities with the host, except for the cell wall, which limits 
the exploitation of fungal-specific targets. [13] 
Compared to the wide range of antibacterial drugs present in the pharmaceutical market, the 
number of available drugs against fungi is considerably limited. Antifungal drugs target 
various stages of metabolic pathways and they can be classified in different groups depending 
on their structure: [5, 6] 
➢ Polyenes: the most known polyene drug is called Amphotericin B (AmB). Polyenes 
target the ergosterols and thus destabilize the plasma membrane of fungal cells and 
they initiate cell lysis. One of the advantages of AmB is that fungi rarely develop 
resistance, although AmB is compromised with high toxicity to the host. [14]  
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➢ Azoles: this group can be divided in two groups, the azoles with one or two nitrogen 
atoms (indole, benzimidazole, imidazole, etc…) and the ones with three nitrogen 
atoms like triazoles. They target the ergosterol biosynthesis pathway by blocking a 
key enzyme (Erg11p), hence killing the fungi. Fluconazole (6) or Voriconazole (7) are 
the most common antifungal drugs belonging in this group. [15] 
 
 
 
➢ Echinocandins: a new type of antifungals with a lipocyclopeptide structure. The most 
known is caspofungin B (8). Echinocandins inhibit the synthesis of β-D-glucan, a cell-
wall component. One of their main advantages is their lower toxicity compared to that 
of polyenes. [16, 17]  
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➢ Allylamines: this kind of antifungals inhibit squalene epoxidase, an enzyme required 
for ergosterol synthesis. Naftifine (9) and Terbinafine (10) belong to this group. [6]  
 
 
It is worth noting that the number of antimicrobial and antifungal agents approved by the 
United States Food and Drug Administration (FDA) and the European Medicines Agency 
(EMA) has sharply decreased over the last 25 years. [18] The last antifungal drug approval by 
the FDA dates from March 2015, when Cresemba was accepted for the treatment of invasive 
aspergillosis and invasive mucormycoses in adults. Therefore, the finding of new antifungals 
or new strategies to restore the effectiveness of known antifungals has become a major issue. 
[19, 20] 
 
1.3. Identification of new antifungal drugs 
Historically, many drugs present in the pharmaceutical market were originally isolated from 
natural sources. Nowadays, in contrast, biologically relevant compounds are usually 
generated by means of synthetic medicinal chemistry and computational design, which has 
vastly increased the efficiency of the drug-discovery process. [21, 22] 
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Combinatorial chemistry is a useful technology in medicinal chemistry. Its basic principle is 
the preparation of a large number of related compounds by parallel synthesis, which is 
followed by high-throughput screening to identify the most promising compounds for further 
development.  
However, the screening of a large number of structurally diverse drugs is neither economical 
nor efficient.   
Then, “how can we design economically viable drugs maintaining or improving efficacy?” [23] 
The approval of “scaffold hopping” is a valuable tool in drug development to generate 
focused compound collections by modifying the core structure of known active compounds.  
In this way, there is no need to synthesize a large numbers of compounds, but rather to 
progressively improve hit rates by exploring molecular space. [24, 25]  
Within this strategy there is a subcategory, the target-family oriented collections that consist 
of compounds specifically designed to target certain protein families. This new focused 
collection may potentially be more effective than the initial active compound.  
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2. OBJECTIVES 
The aim of this work is the design, synthesis and evaluation of novel lead structures, which 
provide better biological activities and lower cytotoxicities compared to a previously found 
lead structure against Candida species. 
The design and synthesis of novel lead compounds was based on focused target-family design 
and supported by solid phase and solution phase combinatorial organic chemistry. 
This work is divided in two sections each with a starting lead compound. 
 
The first section (A) is focused on the human antimicrobial peptide belonging to the 
cathelicidin family, called LL-37. Its characteristics are discussed in the next chapter. 
 
In section (B), a series of (S)-2-aminoalkyl benzimidazoles, which are non-toxic to cell lines 
and exhibit antifungal activity against a set of significant clinical isolates of Candida spp, 
were synthesized. They were investigated for biological activity using a high-throughput 
activity-selectivity assay carried out at the Fraunhofer Institute in Stuttgart in 2011. [26] After 
screening, it was found that the active (S)-2-(1-aminoisobutyl)-1-(3-chlorobenzyl) 
benzimidazole, gave IC50 (half inhibitory concentration) and CC50 (half cytotoxicity 
concentration) values of 0.75 µM and 97.5 µM respectively (Figure 2). [20] This lead molecule 
was used for designing new (S)-2-aminoalkyl-benzimidazole analogues. 
 
 
 
Figure 2. The antifungal compound (S)-2-(1-aminoisobutyl)-1-(3-chlorobenzyl)-benzimidazole structure (or 
EMC120B12). Initial hit identified on a previous high-throughput activity-selectivity assay. 
 
 
Based on the scaffold hopping approach, indoles a, triazoles b and imidazo[1,2-a]pyridines c 
(Figure 3),  have been synthesized. These scaffolds have been selected for their high 
probability to exhibit biological activity. 
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Figure 3. General structures of the investigated scaffolds 
 
At the end of each of the two sections (A) and (B), there is a full chapter summarizing the 
biological screenings of all compounds designed and synthesized in this work against several 
Candida species in collaboration with project partners. 
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3. ANTIMICROBIAL PEPTIDES – SECTION A 
3.1 Introduction Antimicrobial Peptides (AMPs) 
Antimicrobial peptides can be mostly found in the host defence systems of a wide range of 
species, including amphibians, mammals, bacteria and fungi. [27]  
To date, there are more than thousand peptides identified in nature and listed in the 
Antimicrobial Peptides Database (http://aps.unmc.edu/AP/main.php). These natural weapons, 
also called host defence peptides are very diverse in their sequences, length (normally short) 
and structures (linear or cyclic due to intramolecular bridges, with a variety of secondary 
structures) but generally they seem to adopt an amphipathic conformation with opposing 
hydrophobic and polar or charged faces that allows them to interact and disrupt selectively 
negatively charged microbial membranes. [28, 29] The functions of AMPs are very wide. They 
can be antibacterial, antiviral or antifungal or exhibit anticancer properties. They have been 
presented as promising noble class of antibiotics. [30] 
It is known that humans produce three natural classes of AMPs, histatins, defensins and 
cathelicidins. [31]  
• Histatins: expressed in saliva, are peptides rich in histidine residues and with good 
fungicidal activity. [32] 
• Defensins: expressed in epithelia cells, are small, cysteine-rich (allowing them to form 
disulfide bonds) cationic and amphipathic peptides with good antimicrobial and 
fungicidal activity. [33] 
• Cathelicidins: like defensins, are expressed in epithelia and in phagocytic cells are 
small, cationic and amphipathic peptides with high heterogeneous structural features 
in comparison to the two others AMPs groups. [34]   
Whilst other mammals secrete several peptides from all three families, in mice and humans 
only one example of cathelicidin peptide is produced. For mice it is named CRAMP 
(Cathelin-Related Antimicrobial Peptide) and for humans, it is named LL-37. Its importance 
is not only in its antimicrobial properties but also in its modulation of the immune system.  
 
3.2. Cathelicidins 
Cathelicidins are a large family of antimicrobial and immunostimulatory peptides. [35, 36] The 
term cathelicidin was introduced in 1995 by Zanetti [37] to describe molecules both containing 
the cathelin domain and a C-terminal antimicrobial domain. Its name comes from an acronym 
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for Cathepsin L Inhibitor but also can be named as CAMP, referring to Cathelicidin 
Antimicrobial Peptide. 
All members of this family are synthesized as a preproprotein comprising a signal peptide, a 
highly conserved N-terminal prosequence termed cathelin domain and a highly variable C-
terminal peptide domain in which the antimicrobial activity is located (Figure 4). [35, 38, 39]  
 
 
 
Figure 4. Sequence of the CAMP (Cathelicidin AntiMicrobial Protein) gene product. A) Full length of the 
Cathelicidin precursor composed by a signal peptide (orange, ≈ 30 Amino acids, aa), N-terminal Cathelin 
domain (pink, ≈ 94-144 aa) and a C-terminal Antimicrobial peptide LL-37 (green, ≈ 12-100 aa). B) The Amino 
acid sequences for each of the three parts that formed the Cathelicidin precursor. 
 
 
The mature C-terminal antimicrobial peptide ranges from 12-100 amino acid residues and 
diverse secondary structures are mostly found. The most common are the linear antimicrobial 
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peptides with an α-helix amphipathic structure like the human AMP LL-37, but also the are 
two other groups being flat β-sheet structures stabilized by disulfide bonds (e.g. Protegrin) 
and peptides rich in one amino acid like proline, arginine or tryptophan (e.g. Bac7, rich in 
proline and Indolicidin, rich in tryptophan). 
Natural Killer (NK) cells and mast cells constitutively express the cathelicidin protein and 
store the precursor in granules. Activation of TLR(s) (Toll-like Receptors), immune receptors 
that recognize pathogens, and cell damage provides a trigger that activates the cell to 
degranulate. This leads to the release of the inactive peptide precursor in the extracellular 
environment where it can be processed by specific proteases into the active antimicrobial 
peptide. [40]  
 
3.3. Human antimicrobial peptide LL-37 
3.3.1. Introduction 
LL-37 (name based on the first two amino acids in the sequence followed by the number of 
total residues in the peptide), also designed hCAP18 (terminology applied as an alternative to 
LL-37; containing a mass of 18 kDa before processing) is generated from the proprotein form 
hCAP18 encoded by the CAMP gene [41] hCAP18. Following the excision of the signal 
peptide, this proprotein is stored in neutrophil granules and epithelial cells until activated 
through cleavage by the serine protease, specifically, proteinase 3. [42]  
Interestingly, after cleavage of LL-37, the cathelin domain has shown antimicrobial 
properties highlighting how evolution has maximised the antimicrobial function of hCAP18. 
[43] 
As its name indicates, LL-37 contains a sequence of 37 amino acid residues: 
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES adopting an α-helical structure in 
lipid membranes, micelles and ions but being a random coil in pure water. [44] At 
physiological pH, 16 of its 37 residues are charged, namely 6 Lys and 5 Arg residues carry 11 
positive charges, while 3 Glu and 2 Asp residues bear 5 negative charges. Based on that, the 
resulting net charge at physiological pH is positive (6+). 
 
Although LL-37 is described as the sole human cathelicidin, other cleavage sites exist leading 
to different mature peptides. For example, peptides KR-20, RK-31 and KS-30 (table listing 
peptides in appendix) are found in human sweat and skin cells and they are a shorter version 
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of LL-37. [42] Despite being shorter, they still show biological activity which has opened a 
new aspect of study. 
LL-37 has been shown to have multitude roles in our body. It is well known for its 
antibacterial effects [45, 46] but also has other antimicrobial properties including antifungal, [42, 
47] antiviral, [48 - 49] anticancer, [50 - 51] and inhibition of biofilm formation. [52]  
LL-37 has also been associated with modulation of the expression profiles of elements of the 
immune system, regulation of the inflammatory response, stimulation of wound healing, 
chemotaxis, apoptosis, angiogenesis and cancer tumourgenesis. [53 - 54] 
LL-37 is sometimes referred as “alarmin” due to many of these immunomodulatory 
functions, which appear to occur at concentrations below the levels required for antimicrobial 
activities suggesting that the immune response may arise form interactions with more specific 
receptor proteins. [55] 
 
3.3.2. Structure 
LL-37 is a classical amphiphilic α-helical peptide. At low concentrations (< 10-5 M) it is a 
largely unfolded monomeric peptide but at higher concentrations it adopts the α-helical 
oligomeric structure. [56] It is believed that the hydrophobic effect involving shielding of the 
hydrophobic face from the bulk medium is the cause of this switch. [57] 
Some NMR studies in micelles with LL-37 have shown some flexibility within the central 
helical core, this part of the sequence is described as a bent helix [58] and corresponds to an 
area of high glycine content in related primate orthologs. [59] 
The existence of this helical bend between residues 14-16 within LL-37 (Figure 5) allows 
classifying the human cathelicidin into three structural and functional regions:  
1. The N-terminal unit (residues 1-13, labelled as I in Figure 5) is a relatively 
disordered non-polar / hydrophobic section which has been implicated in chemotaxis, 
in peptide oligomerization, in proteolytic resistance and hemolytic activity. [60, 61, 44] 
2. The central bulk of the peptide (residues 17-31, labelled as II) is α-helical and 
contains the antimicrobial, antifungal and antiviral effect. [60, 62, 63] 
3. The C-terminal end (residues 32-37, labelled as III) is described as a short 
hydrophilic tail unit that facilities the tetramer formation at physiological pH. [64, 65] 
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Figure 5. A) Helical wheel diagram for LL-37. B) Ribbon representation of the LL-37 structure with 
hydrophobic side chains labelled. The helical bend is indicated by an arrow and the three structural regions are 
labelled I, II and III. Figures extracted from Wang, G.S. J. Biol. Chem., 2008, 283, 32637-32643. 
 
By using NMR techniques it is possible to show that the predominance of hydrophobic 
residues in the N-terminal region and the hydrophilic amino acids at the C-terminus make 
terminal sections of LL-37 unstructured in lipid micelles and therefore not essential for 
antibacterial activity. [64, 66] 
 
3.3.3. Mode of action 
LL-37 has high diversity compared to other α-helical AMPs due to the lack of specificity 
when it easily binds to both microbial and mammalian membranes. [67 - 68] 
In general, antimicrobial peptides target bacterial membranes rather than mammalian, simply, 
due to the fundamental difference in the composition of the cell wall. Mammalian cells 
contain only a cell membrane formed by a phospholipid bi-layer, being hydrophilic to the 
external part of the membrane and hydrophobic in the inner wall. 
Bacteria, though, contain a cell membrane and an other outer membrane called cell wall. A 
sub-classification within bacteria cell walls exists: Gram-negative and Gram-positive.  
Gram-positive bacteria possess a cell wall outside the membrane while Gram-negative 
bacteria contain an outer secondary membrane (Figure 6). Furthermore, Gram-negative cell 
walls contain lipopolysaccharides whilst Gram-positive bacteria present a surface of teichoic 
acids. In both bacteria classes, negatively charged cell surfaces predominate.  
In contrast, most mammalian cell membrane have an outer leaflet comprised of zwitterionic 
phosphatidylcholine (PC) and sphingomyelin phospholipids (SM), whilst the inner leaflet is 
composed of phosphatidylserine (PS) leading to an essentially neutral surface. [57, 69] 
A B 
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Based on that, the negative charge associated with bacterial cells means that cationic AMPs 
are primarily attracted to the pathogenic membrane (negatively charged) rather than to that of 
mammalian cells (neutral charged).  
 
 
Figure 6. Comparison of the thin cell wall of Gram-negative bacteria (left) with the thick cell wall of Gram-
positive bacteria (right). Adapted figure from public domain. 
 
For antimicrobial peptides such as LL-37, three mechanisms for disrupting membranes has 
been proposed: [61, 57] 
 
1) The barrel-stave model: this model requires that membrane bound peptides 
recognise each other, oligomers forming structured transmembrane pores within the 
membrane through which essential cellular components can escape.  
2) “Carpet-model”: peptides coat the phospholipid membrane surface until a 
threshold concentration is reached when the peptide either permeates the membrane in 
a detergent like manner or leads to the formation of toroidal holes. In the former, the 
peptides bind parallel to the membrane surface such that the positively charged amino 
acids of the peptide can maintain constant contact with the membrane (Figure 7). 
3) Toroidal-pore mechanism: follows a similar initial pathway also involving 
curvature of the membrane. In this case, self-association of the membrane associated 
peptides leads to the formation of toroidal (doughnut like) holes in the membrane. [70] 
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Figure 7. Mechanisms for insertion of LL-37 into membranes: A) Monomers or aggregates of peptides approach 
to the membranes. B) Barrel-stave mechanism: the peptides form a large cylindrical pore lined with peptide 
oligomers inserting themselves perpendicular to the membrane. C) Carpet mechanism: peptides coat the 
membrane surface until a critical concentration when either the membrane is disrupted in a detergent like 
manner. D) Peptides bind to the phospholipids headgroups that induces such a high degree of membrane 
curvature forming the toroidal pores. (Burton, M.F and Steel, P; Nat.Prod.Rep., 2009, 26, 1572-1584). 
 
LL-37 can interact with mammalian cell membranes as well despite not being negatively 
charged and stimulate a wide range of cell receptors and transcriptional factors. Significantly, 
it is through stimulating such targets that the human natural product exerts its 
immunomodulatory effects. [71, 72] 
For the mode of action of AMPs two possibilities have been described: either AMPs binding 
triggers a chain of events leading to the displacement of a signalling molecule which then 
activates its cognate receptor or insertion of the AMPs into the lipid structure triggers an 
allosteric change to the receptor structure thus modifying the activity. [73 - 74] 
 
3.3.4. Modifications 
Due to its potential roles in many therapeutic areas, LL-37 has been extensively studied. 
Fragments of this molecule are usually denoted by the one-letter-code abbreviation of its two 
initial amino acids followed by the number of residues. Tossi and co-workers [59] have 
determined more than a dozen cathelicidin sequences, each one with different biological 
activity. Their conclusion is, that the antimicrobial and immunomodulatory effects of the 
  
 
 
22 
peptide are interlinked and dependent on the key properties of charge, helicity and 
amphipathicity. 
 
3.3.4.1. Modification of the N-terminus 
As described in Section 3.3.2. Structure, the predominance of hydrophobic residues in the N-
terminal region is not essential for antibacterial activity considering the absence of affinity for 
membranes interaction. Johansson et al., [44] along with their studies of the wild type peptide, 
investigated two truncated variants, FF-33 and SK-29, which lacked 4 and 8 residues on the 
N-terminus, respectively, making the fragments more hydrophilic than the full-length peptide 
but less effective in killing bacteria. However, despite not being biologically active against 
bacteria or fungi, they were crucial for the immunological activity of LL-37. 
  
RK-31 and KS-30 fragments lacking the hydrophobic N-terminal region, were found in 
human sweat and skin cells. They showed activity against some bacteria (S. aureus and E. 
coli) and some fungi (C. albicans) but also hemolytic activity. [42] 
Our synthetic analogues were based on those two fragments and especially on KS-30, which 
gave the best inhibitory activity against Candida. [42] Therefore, most of the analogues start 
with KS followed by the rest of the LL-37 sequence, varying some other regions of the main 
peptide.  
Ac-KS-30 (17) and Ac-KS-30-NH2 (18), which were N-acetylated at the N-terminus (17) and 
also C-modified by an amide at the C-terminus (18) were designed in order to possible 
enhance the stability against exoproteases.  
  
3.3.4.2. Modification of the C-terminus 
It is considered that the short hydrophilic tail unit of the LL-37 facilities the tetramer 
formation at physiological pH and therefore the better affinity to the cell membranes. [40] 
Majority of all analogues used in this work maintain the C-terminus untouched. KS-30-NH2 
(16) and Ac-KS-30-NH2 (18) are peptide amides with no change in the sequence. KS-22 (22), 
FKG13-13 (33), FKF12G-13 (34), FKN3-13 (35) and KS-26 (23), are C-terminally truncated 
peptides. 
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3.3.4.3. Modification of the bend section 
NMR studies have shown that between residues 14 to 16 a small bend exists, which gives 
some flexibility to the peptide. [58] 
The flexibility might due to the high glycine content. The region was modified by:  
➢ Changing glycine by hydrophobic alanine: KSA7-30 (13) and KSA9-30 (25) 
➢ Adding an additional glycine residue: KSG8-30 (15) 
➢ Moving the bend to the N-terminus of the peptide: KE-23 (27) 
 
3.3.4.4. Modification in the net charge 
LL-37 at physiological pH has a positive net charge of + 6. It is well known that 
antimicrobial peptides with different net charge have different biological activity. [40] 
Therefore, the immunomodulotary and antimicrobial effects of peptides may be interlinked 
and dependent on their charge.   
To address this subject, we have designed some analogues with more and less positive net 
charge than + 6: KK-31 (19), KSA29-30 (24) and KS-27 (26) (charge + 7); KSA3-30 (20), 
SK-29 (29), AS-30 (11), KE-28 (30) and KF-22 (32) (charge + 5); KE-23 (27), FF-22 (28) 
and FK-21 (31) (charge + 4); FKG13-13 (33), FKF12G-13 (34) and FKN3-13 (35) (charge + 
3). 
 
3.3.4.5. Modification of the core section 
Wang’s group [58] using also NMR, identified the smallest active peptide within LL-37 
sequence which still gives antimicrobial activity. Called FK-13, it was designed as the “core” 
of the LL-37 structure. Based on that, the residues that comprise the core of the long 
analogues were not varied. Only a few analogues, in which the length coincided with FK-13 
or KR-12, have been slightly modified. The only variations done were focused on changing 
the positive net charge, FKG13-13 (33), adding hydrophobic residues, FKF12G-30 (34) or 
adding polar side chains, FKN3-13 (35).  
 
3.3.4.6. Other modifications 
The presence of the residue serine in position 9 in the full sequence of LL-37 disrupts the 
hydrophobic region of the peptide. To study this disruption and its effects on the biological 
activity, the analogue KF-30 (12) was designed. 
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The aromatic hydrophobic phenyl residues of F5, F6, F17 and F27 of LL-37 could have an 
essential role for the interaction with phosphatidylglycerols in the bacteria membrane. [58] 
Mostly all the analogues are based on KS-30, which lack of F5 and F6 but not F17 and F27. 
We assumed that F5 and F6 were less important, as the shortest analogues of LL-37 (KR-12 
and FK-13) still produce some biological activity despite the absence of F5 and F6.  
 
3.4. Synthesis of LL-37 analogues 
3.4.1. Solid phase peptide synthesis 
Bruce Merrifield pioneered in 1963 the solid phase synthesis, for which he won the Nobel 
Prize in 1984. [75] His concept has spread in many fields, including in parallel organic 
chemistry. 
The basic of the technique consists in constructing the peptide through successive addition of 
protected amino acids, anchored to an insoluble polymer through its C-terminus (Figure 8).  
The most benefits of SPPS are the separation of the intermediate polymer-bounded peptides 
from soluble reagents and solvents by filtration and washing; excess of reagents can be 
employed to help to drive reactions to completion and the physical losses can be minimized as 
the peptide remains attached to the support throughout the synthesis. There are several 
limitations. By-products arising from incomplete reactions or side reactions can accumulate 
on the resin during chain assembly and contaminate the final product. Also, the yield of the 
reaction will decrease in longer peptides. [76, 77] 
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Figure 8. The solid phase peptide synthesis (SPPS) principle. [78] 
 
The C-terminal amino acid residue of the target peptide is attached to an insoluble support 
(resin) through a linker via its carboxy group (Figure 8). Any functional groups in amino acid 
side chains must be protected with permanent protecting groups that are not affected by the 
reactions conditions employed during the peptide chain assembly. The temporary protecting 
group masking the α-amino group during the initial resin loading is removed. The next amino 
acid is introduced with the carboxy group of this amino acid being activated with coupling 
reagents for amide bond formation. After coupling, excess of reagents are removed by 
washing and the protecting group from the N-terminus of the last amino acid is also removed. 
This process is repeated until the desired peptide sequence is assembled. In a final step, the 
peptide is released form the support and the side-chain protecting groups are removed at the 
same time using appropriate conditions.  
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The analogues were synthesized using a fully automated parallel synthesizer (SyroII) and 
following a standard Fmoc/tBu procedure.  
In all cases the linker used was 2-chlorotrityl to a crosslinked divinylbenzene-polystyrene. For 
peptides KS-30-NH2 and Ac-KS-30-NH2, Rink Amide linker was used in order to obtain the 
C-terminal end of the peptide as a carboxamide.  
The permanent protecting groups of the amino acids side chains were the following: Trt for 
Asn and Gln; Boc for Lys; Pbf for Arg; OtBu for Asp and Glu and tBu for Ser and Thr. 
The amino acids were dissolved in DMF and with OxymaPure® (0.5 M) to minimize 
racemization and using as activating reagents DIC and TCTU. SyroII instrument followed the 
protocol (described in “6.1.2.3.” Experimental part, Section A) composed by flushing the 
needle for two cycles (2 times), removing the Fmoc group (N-protection) with a solution of 
30 % piperidine in DMF and adding DIPEA, activating reagent (1st coupling: DIC 3 M in 
DMF, and 2nd coupling: TCTU 0.4 M in DMF) and the Fmoc-amino acids (0.5 M). This 
procedure was repeated until the sequence was finished.   
Once the last amino acid was coupled, the Fmoc protecting group was split off. Simultaneous, 
cleavage and full deprotection of the linear peptides was carried out by acidolysis with a 
mixture of TFA/TIS/H2O or TFA/Reagent K for 90 min. 
The filtrate was collected and the resin was washed with DCM and the peptides were 
precipitated from TFA solution with diethyl ether, isolated by centrifugation and the 
supernatant was removed by decantation. This procedure was repeated at least three times to 
assure the removal of the acidolytic mixture from precipitated peptides.  
The pellets were redissolved from tBuOH:H2O (4:1, v/v) and lyophilized.  
Finally, the crude peptides were purified by preparative HPLC and the products (purity > 
95 %) were characterized with analytical HPLC and MS. 
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3.5. Antifungal screenings – AMPs  
3.5.1. Objective 
The objective in this part was to determinate the biological effect of the synthetic LL-37 and 
analogues against Candida species. Several biological assays for antifungal activity were 
carried out with all peptides. These compounds were investigated by high-throughput 
screening, to define the minimum inhibitory concentration (MIC) and to evaluate their 
antifungal activity against clinical isolates of Candida species. 
 
3.5.2. High-throughput screening (HTS)1 
The fluorimetric high-throughput screening (HTS) was based on published procedures [26] and 
should give a general overview of the effect of the compounds against Candida albicans 
SC5314.  
The assay mimics the natural interaction of host-pathogen by incubation of the pathogen (this 
case Candida albicans SC5314) in the presence of a host cell line (e.g. HeLa cells). In 
parallel, this assay is able to control the tolerability of antifungal agents by host cells and the 
antifungal activity. Therefore, the survival of the HeLa cells culture (host) in the presence of 
Candida albicans (pathogen) and the respective compounds (LL-37 and analogues) is 
measured directly instead of measuring the inhibition of enzymatic functions of Candida 
albicans or the growth retardation alone. This screening assay covers potential in vitro targets 
of both the pathogen and the host (Figure 9). [79] 
HeLa cells were chosen in this assay due to their characteristic robust growth behaviour and 
reproducible sensitivity to Candida albicans strain SC5314. Amphotericin B was used as a 
positive control. 
 
1 In collaboration with Project partner, Fraunhofer IGB, Stuttgart. 
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Figure 9. HTS used in Fraunhofer Institute. Plates were incubated for 5 days, 5 % CO2 at 37 °C. After washings 
with PBS, the dye FDA (Fluorescein diacetate) was added and the fluorescence was immediately read by 
spectrofluorometer. The results were shown as a chart calculated by software. Figure handed over by Fraunhofer 
IGB. 
 
Basically, in a 96 well plate, HeLa cells were previously grown before starting the assay.  
Afterwards, in each well Candida albicans SC5314 (50 CFU) and 10 µM concentration for 
initial screening of the peptides were added. The plates then were incubated for 5 days at 37 
°C in a 5 % CO2 humidified incubator.  
After that time, the plates were washed with PBS and the dye FDA was added to each well. 
The plates were immediately read in a spectrofluorometer (ʎ = 485 – 535 nm, sensitivity 50), 
every 60 seconds for 3 minutes.  
The read out is an area under the curve, calculated by the software that gives the amount of 
HeLa cells that are alive measured by the FDA released. The values obtained for the cell 
vitality control were defined as 100 % cell viability and all the samples were normalized to 
this cell vitality control (Table 1). 
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Table 1. Layout of the plate. Cell viability control contained only HeLa cells. Fungus control contained HeLa 
cells and C. albicans. Positive control contained HeLa cells, C. albicans and Amphotericin B. Each peptide was 
studied in duplicate. 
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3.5.2.1. Results 
Screening graph 
Table 2. Results obtained from the fluorometer readings for all LL-37 analogues. The percentage represents the 
amount of HeLa cells alive.  
 
 
 
The analogue that showed some activity (almost 50 % of cell viability) was KS-30-NH2 (16) 
(Table 2). This analogue corresponds to the control KS-30 with an amide C-terminus. 
 
 
 
 
 
1 2 3 4 5 6 7 8 
A LL-37  
13 % 
RK-31  
3.5 % 
KSA7-30 
(13) 
0 % 
KSA3-30 
(20) 
12 % 
KSA9-30 
(25) 
0 % 
SK-29 (29) 
7 % 
FKG13-13 
(33) 
7 % 
Ac-KS-30 
(17) 
8.2 % B 
C FK-13 
11 % 
KS-30 
8.5 % 
KSR8-30 
(14) 
0 % 
KSF17-30 
(21) 
4 % 
KS-27 (26) 
2 % 
KE-28 (30) 
4 & 
FKF12G-13 
(34) 
8 % 
Ac-KS-30-
NH2 (18) 
13 % D 
E KR-12 
16.5 % 
AS-30 (11) 
0 % 
KSG8-30 
(15) 
0 % 
KS-22 (22) 
11 % 
KE-23 (27) 
3 % 
FK-21 (31) 
12.6 % 
FKN3-13 
(35) 
7 % 
KS-26 (23) 
1.3 % 
F 
G KR-20 
7 % 
KF-30 (12) 
2 % 
KK-31 (19) 
7 % 
KSA29-30 
(24) 
7 % 
FF-22 (28) 
24.5 % 
KF-22 (32) 
31 % 
KS-30-NH2 
(16) 
47 % H 
  
 
 
30 
3.5.3. Minimum inhibitory concentration (MIC) 
To explore their antifungal activity only on Candida species (pathogens) without the presence 
of any host, the minimum inhibitory concentration (MIC) was studied.2  
Minimum inhibitory concentration is described as the lowest concentration of antifungal 
agent that inhibits the visible growth of a microorganism in 18-24 h.  
The species used for this assay were C. glabarata ATCC2001, C. parapsiolosis ATCC22019 
and C. krusei ATCC6258 beside the C. albicans SC5314. Those species were selected due to 
their resistance to azoles and other antifungal drugs, such as fluconazole and voriconazole, 
which were used as controls. 
All peptides were titrated at 8 different concentrations and coincubated with the yeast cells for 
24 h at 30 °C.  
The range of peptide concentrations was from 64 - 0.125 µg/ml (0.05 – 40 µM). 
After incubating the plates for 24 h at 30 °C the OD600 values were measured using a plate 
reader (Victor3, Biotek,Winooski, USA) (Table 3): 
 
• Translation of readouts in percentage of fungi growth: 
Table 3. Translation of the crude data from the plate reader values into percentages. E.g: cell A1 after the 
readings, indicates that the compound was not able to inhibit the growth of C. albicans SC5314 because the 
growth was 99.7 %. 
 
 
 
 
 
 
 
 
2 This study was carried out at the Medical University Vienna, Max F. Perutz Laboratories Vienna. 
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3.5.3.1. RESULTS 
The MIC curves were calculated for each peptide based on the plate read out at OD600. 
 
Figure 10. Minimum inhibitory concentration (MIC) representation, showing the biological effect of the 
synthetic analogues against Candida species. Yellow line C. albicans SC5314; Green line C. glabrata 
ATCC2001; Pink line C. parapsilosis ATCC22019 and purple line C. krusei ATCC6258.  
 
 
Figure 11. Minimum inhibitory concentration (MIC) representation, showing the biological effect of the 
synthetic analogues against Candida species. Yellow line C. albicans SC5314; Green line C. glabrata 
ATCC2001; Pink line C. parapsilosis ATCC22019 and purple line C. krusei ATCC6258.  
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Figure 12. Minimum inhibitory concentration (MIC) representation, showing the biological effect of the 
synthetic analogues against Candida species. Yellow line C. albicans SC5314; Green line C. glabrata 
ATCC2001; Pink line C. parapsilosis ATCC22019 and purple line C. krusei ATCC6258.  
 
 
 
 
Figure 13. Minimum inhibitory concentration (MIC) representation, showing the biological effect of the LL-37 
against Candida species. Yellow line C. albicans SC5314; Green line C. glabrata ATCC2001; Pink line C. 
parapsilosis ATCC22019 and purple line C. krusei ATCC6258.  
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To resume these graphs: 
Table 4. Concentration of the analogues that showed activity against Candida spp at the minimum inhibitory 
concentration (MIC). 
 
 
 
The control peptide FK-13 was the only compound that showed some growth inhibition for 
all four Candida species tested. FK-21 (31) analogue was also active to all Candida species 
but C. glabrata. Both compounds, FK-13 and FK-21 (31), were active at the highest 
concentration 64 µg/ml (37.2 and 24.5, µM, respectively) and both compounds inhibited the 
growth of C. krusei at 32 µg/ml (18.6 and 12.2 µM) (Table 4). 
FF-22 (28), FKF12G-13 (34), KF-22 (32) and FKG13-13 (33) analogues were active only 
against C. krusei at highest concentration (64 µg/mL, 23.2, 38.7, 23.2 and 39.5 µM, 
respectively). 
FKN3-13 (35) analogue was active only against C. glabrata at highest concentration (64 
µg/ml, 38.2 µM). KS-22 (22) analogue was active only to C. parapsilosis and at highest 
concentration 64 µg/ml (23.2 µM) and control KR-20 was active for two Candida species, 
glabrata and krusei at highest concentration (64 µg/ml, 26 µM). 
LL-37 was not active for the Candida spp we tested and neither at the range of concentration 
we used (Table 4). 
 
3.5.4. Screening of clinical Candida spp isolates 
Compounds exhibiting growth inhibition during the MIC analysis were selected for further 
screening. These compounds were tested against several clinical isolates of Candida spp. 
Therefore, clinical isolates were arrayed in a 96 well pattern shown in Figure 14. 
 
 Fungi 
Peptides C.albicans 
SC5314 
C.glabrata ATCC2001 C.parapsilosis 
ATCC22019 
C.krusei ATCC6258 
LL-37 - - - - 
FK-13 64 µg/ml 64 µg/ml 64 µg/ml 32 µg/ml 
KR-20 - 64 µg/ml - 64 µg/ml 
FK-21 (31) 64 µg/ml - 64 µg/ml 32 µg/ml 
KF-22 (32) - - - 64 µg/ml 
FF-22 (28) - - - 64 µg/ml 
KS-22 (22) - - 64 µg/ml - 
FKG13-13 (33) - - - 64 µg/ml 
FKF12G-13 (34) - - - 64 µg/ml 
FKN3-13 (35) - 64 µg/ml - - 
!
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Figure 14. Layout of clinical Candida spp isolates screening plate. Columns 1-2, C. albicans isolates; Columns 
3-4, C. glabrata; Columns 5-6, C. parapsilosis and columns 7-8, C. krusei. Purple background corresponds to 
lab strains. The remaining columns show results of different Candida species like tropicalis or lusitaniae. All 
clinical isolates come from Vienna General Hospital expect blue background cells that come from Karl Kuchler 
lab, specific for azole resistance.  
 
The screening plates with 100 µl of medium YPD were supplemented with 100 µl of the 
respective antifungal peptide diluted in medium and distilled H2O (all wells except the last 4 
of the plates, see Figure 14) with the concentration determined in MICs assay (Table 4). To 
assure the stress of all standard strains without inhibiting their growth completely, the 
concentration used for all compounds was the highest, 64 µg/ml.  
The clinical isolates were arrayed in a 96 well pattern on a solid media square. Using a Singer 
RoTor HDA robot, they were transferred to the 96 well plate holding the 200 µl (YPD media 
+ peptide) and incubated 24 h at 30 °C.  
The readings were carried out after those 24 h of incubation by measuring the OD600 on the 
Victor3 plate reader.  
The empty wells contained only media as a blank. The average of their values was subtracted 
from the readouts of all walls prior to analysis.  
 
3.5.4.1. Results 
The results of the screening of clinical Candida spp isolates were summarized in a table 
specifying the grade of growth of the fungi with the peptide (Table 5).  
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A SC5314 KK017 ATCC2001 KK060 ATCC22019 KK136 ATCC6258 KK264 KK268 KK014 KK158 KO1054 
ypk1Δ 
B KK001 KK018 KK003 KK070 KK002  
 
KK190 KK107 KK273 KK007 KK036 KK170 KO519 
slt2Δ 
C KK005  KK019  KK004 KK079 KK012  
 
KK196 EMPTY KK166 KK067 KK038 KK181 KO172 
wsc1Δ 
D KK008  KK020 KK006 KK088 KK030  KK207 KK147 KK198 KK112 KK062 KK189 
E KK009 KK021 KK033 KK113 KK041 KK209 KK163 KK251 KK162 KK063 KK167 
F KK010 KK024 KK045 KK114 KK048 KK210 KK165 KK252 KK187 KK130 KK073 
G KK011  KK025 KK047 KK115  
 
KK056 KK212 KK197 KK253 KK240 KK132 #26 
HTL 
H KK013 KK026 KK059 KK122 KK096 KK213 KK246 KK254 KK016 KK142 KO160 
pdr1Δ 
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Table 5. Summarized results for the growth of the fungi cells with the peptides at their MIC concentration. Red 
colour indicates that the growth of the fungi was over 50 %. The pink colour indicates that the effect of the 
peptide was very poor and the growth of the fungi was between 30-50 %. Bright green indicates that the growth 
of the fungi was between 0-30 %. The other green colour collects the other different Candida species and 
corresponding to the growth of the fungi between 0-50 %.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fungi C. albicans Isolates C. glabrata Isolates C. parapsilosis isolates C. krusei isolates Other species 
Peptides      
FK-13 
(37.2 µM) 
Poor effect None effect None effect Strong effect 
Some species: 
C. tropicalis 
C. lusitaniae 
C. kefyr 
KR-20 
(26 µM) 
Poor effect None effect None effect Poor effect, only lab strain 
Some species: 
C. Kefyr 
C. tropicalis 
FF-22 
(23.1 µM) 
None effect None effect None effect Poor effect, only lab strain None effect 
FK-21 
(24.5 µM) 
None effect None effect None effect Poor effect 
None effect 
Only C. tropicalis 
KF-22 
(23.2 µM) 
None effect None effect None effect Poor effect Only C.lusitaniae 
FK-G13-13 
(39.5 µM) 
None effect None effect Very poor effect Poor effect, only lab strain None effect 
FK-F12G-13 
(38.7 µM) 
Not studied Not studied Not studied Not studied Not studied 
FK-N3-13 
(38.2 µM) 
None effect None effect Very poor effect Poor effect, only lab strain 
Some species: 
C. lusitaniae 
C. kefyr 
KS-22 
(25.8 µM) 
None effect None effect Very poor effect None effect None effect 
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3.6. DISCUSSION SECTION A 
After the synthesis of LL-37 (plus controls) and analogues, the peptides were biologically 
studied3 and the results obtained were summarized here.   
➢ Chemical synthesis: The synthesis of all peptides was carried out by automated solid 
phase peptide synthesis. The yields of some analogues were affected not only due to 
length of the sequence but also for the presence of hydrophobic residues.   
 
➢ High-throughput screening: All synthesized peptides were screened at a 
concentration of 10 µM against Candida albicans. Only KS-30-NH2 (16) showed 
some activity, with cell viability over 40 %. Its structure is based on the control KS-30 
but with an amide C-terminal. In comparison to control KS-30, this C-terminal 
modification showed to be more active against Candida albicans SC5314 than the 
control. This modification might be reinforcing the sequence by making it less 
sensible to degradation. [42] Unexpectedly, the other analogue with amide C-terminal, 
Ac-KS-30-NH2 (18) and expected to have similar action, it did not show much activity 
(13 % cell viability). Probably, the effect of the acetyl N-terminal modification is 
counteracting the C-terminal action. This hypothesis was validated with the analogue 
Ac-KS-30 (17), which only had the N-terminal modified but not the C-terminal. Ac-
KS-30 (17) showed to be less active (8.2 % cell viability) than the N,C-modified 
peptide, Ac-KS-30-NH2 (18).  
 
➢ Minimum inhibitory concentration (MIC): The minimum inhibitory concentration 
assay was carried out for all the synthesized peptides and showed that only two 
peptides were able to inhibit the growth of all the tested Candida spp: FK-21 (31) and 
FK-13. Both peptides inhibited the growth for all Candida species at the highest 
concentration tested (64 µg/ml; 24.5 and 37.2 µM, respectively), except for the species 
C. krusei ATCC6258, which was inhibited at 32 µg/ml (12.2 and 18.6 µM). The 
structural difference between the two peptides is the hydrophilic tail unit of the FK-21 
(31). This C-terminal hydrophilic tail has minor influence on the activity of the core 
region. 
Several other peptides inhibited the growth of at least one Candida species such as:  
 
3 Supported by ImResFun partners. 
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- FF-22 (28), KF-22 (32), FKG13-13 (33) and FKF12G-13 (34). They inhibited 
only the growth of the species, C. krusei at high concentration tested (64 
µg/ml; 23.1, 23.2, 39.5 and 38.7 µM, respectively). Their structure is very 
similar, lacking the N-terminal unit, a disordered non-polar / hydrophobic 
section.  
- FKN3-13 (35) was active only against C. glabrata at high concentration (64 
µg/ml, 38.2 µM); KS-22 (22) was active against C. parapsilosis at 64 µg/ml 
(23.3 µM) and the control KR-20 was active against both C. glabrata and C. 
krusei also at its high concentration (64 µg/ml, 26 µM).  
For the rest of the peptides, even LL-37 and other controls, no activity was observed 
at those concentrations. The structure for all the non active peptides mimics the 
control KS-30. They lack the N-terminal unit that is partially responsible for the 
peptide oligomerization and proteolytic resistance. [60] 
In this assay, the analogue KS-30-NH2 (16), which was active during the high-
throughput screening, showed no activity for all Candida species tested at highest 
concentration (64 µg/ml, 17.5 µM).     
 
➢ Screening of clinical Candida spp isolates: In this screening, only the peptides that 
showed activity in the MIC assay were further studied. Their antifungal activity was 
evaluated in a screening with different clinical Candida spp isolates. The 
concentration used was the one obtained in MIC assay. To assure a visual effect for all 
the compounds, the concentration chosen was 64 µg/ml, although the control FK-13 
was active at lower concentration (32 µg/ml).  
FK-13 (37.2 µM) showed to be the most active peptide so far, inhibiting the growth of 
C. krusei clinical isolates over 70 % and C. albicans between 50 – 70 %. For C. 
glabrata and C. parapsilosis species, they were weakly inhibited for FK-13, with less 
than 50 %. The rest of the active peptides did not show any notable inhibition against 
any of Candida species. 
It was observed that the clinical isolates from C. krusei species were more sensitive to 
inhibition (50 – 70 %) for all peptides tested but KS-22 (22). Other Candida species 
studied like C. tropicalis or C. lusitane were also inhibited by almost all the analogues 
except for FF-22 (28), FK-21 (31) (both with identical sequence but differing only in 
one extra phenyl residue), KS-22 (22) and FKG13-13 (33). 
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FKF12G-13 (34) was not studied.  
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4. HETEROCYCLIC DRUGS – SECTION B  
4.1. Scaffold hopping 
The aim of scaffold hopping in medicinal chemistry is the discovery of structurally novel 
compounds based on a known active compound. The core structure of a biologically active 
compound is modified to improve chemical properties and to generate novel compounds. [21, 
80] For example, a replacement of a lipophilic scaffold by a more polar one will increase the 
solubility of the compound; or a change in the scaffold can lead to an improved binding 
affinity in interaction with the target protein; or from the business point of view, a change in 
the central scaffold can lead to a novel structure that can be patentable. [81 - 82] 
Usually, the rational basis for scaffold hopping comes from computational calculations, which 
help to design new potential hits. Many different software programs can offer combinations of 
several approaches like shape matching, pharmacophore searching or fragment replacement 
(Figure 15). [83]   
 
  
 
 
Figure 15. Schematic representation of principal computational approaches to scaffold hopping. [83] 
  
In this work, the scaffold hopping approach has been used to develop novel scaffolds for 
antifungal treatment on Candida species. 
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4.2. Nitrogen containing heterocyclic drugs 
Nitrogen heterocycles are common drug components in the pharmaceutical market and play a 
central role in the design of therapeutic molecules. A wide range of natural products such as 
amino acids, vitamins or nucleic acids, contain nitrogen heterocycles as core structure 
elements, so there are strong efforts in medicinal chemistry to find analogues of these 
structural motifs. The presence of a heterocyclic moiety in a molecule gives the compound 
pharmacokinetic and toxicological properties that can be modulated and therefore utilized to 
optimize potency and selectivity through different strategies like bioisosteric replacements, 
polarity, lipophilicity or aqueous solubility. [84] In addition to this information, Njardarson et 
al. [85] compiled a database of all U.S FDA approved pharmaceuticals focused only on 
structurally unique small-molecule drugs with heterocyclic structure. This analysis of the 
structural diversity among heterocycles showed that at least 60 % of these compounds 
contained N-heterocycles.   
 
4.3. Benzimidazoles  
Benzimidazole is a well-known heterocyclic compound consisting of a benzene and an 
annulated imidazole ring.  
The broad interest for benzimidazoles in medicinal chemistry is well expanded due to their 
diverse biological activity and clinical applications. [86 - 87] Benzimidazole core has five 
positions that can be substituted. Very common are positions 1 and 2, but positions 5 to 7, 
located in the phenyl ring are also easily substituted (Figure 16, A).  
The optimization of benzimidadozole-based structures has resulted in various drugs that are 
currently on the market, such as Omeprazole (proton pump inhibitor, 39), Candesartan 
(hypertension treatment (AstraZeneca), 36), Emedastine or Astemizole (antihistaminic 
activity (Alcon), 37 and 38) (Figure 16, B).   
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A) 
 
B) 
 
 
Figure 16. A) Preferred substitution patterns. B) Pharmaceuticals containing a benzimidazole scaffold. 
 
4.3.1. EMC120B12 - (S)-2-(1-aminoisobutyl)-1-(3-chlorobenzyl) benzimidazole 
The result of a high-throughput screening, which combined the tolerability of human cells 
(HeLa) with the activity against Candida albicans, (S)-2-(1-aminoisobutyl)-1-(3-
chlorobenzyl) benzimidazole (EMC120B12) (Figure 17) exhibited an IC50 and CC50 of 0.75 
μM and 97.5 μM, respectively. [26]  
On the contrary, further SAR studies showed that the (R)-enantiomer was completely inactive. 
 
 
Figure 17. Structure of the active (S)-2-(1-aminoisobutyl)-1-(3-chlorobenzyl)benzimidazole (EMC120B12). 
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4.3.2. Synthesis of substituted benzimidazoles 
Based on EMC120B12, a small collection of compounds was synthesized by systematically 
varying two regions of the core structure without affecting the essential (S)-configuration and 
without changing the free primary amino group. The synthesis was carried out by methods of 
parallel solid phase organic synthesis and based on published procedures. [20] The synthesis is 
summarized in Scheme 1.  
 
 
Scheme 1. Synthesis of the EMC120B12 analogues (Table 6). 
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Table 6. List of the EMC120B12 analogues synthesized.  
Compound R1 R2 Yield (%) Purity (%)* 
EMC120B12 3-Chloro-phenyl iPr 65 98 
BE1 4-Chloro-phenyl Methyl 85 94 
BE2 4-Chloro-phenyl iPr 66 95 
BE3 4-Fluoro-phenyl Methyl 82 90 
BE4 4-Fluoro-phenyl iPr 76 91 
BE5 3-Chloro-phenyl Indolyl 26 88 
BE6 3-Fluoro-phenyl iBu 77 94 
BE7 H-Phenyl iPr 74 97 
BE8 3-Chloro-phenyl iBu 73 89 
BE9 3-Chloro-phenyl Propyl 55 98 
BE10 3-Fluoro-phenyl Propyl 54 98 
BE11 3-Chloro-phenyl 3-Methylthioethyl 31 95 
BE12 3-Chloro-phenyl 4-Hydroxyphenyl 34 97 
BE13 H-Phenyl Methyl 86 85 
BE14 H-Phenyl Phenyl 46 98 
BE15 H-Phenyl Propyl 68 95 
*Purities were determined by HPLC-ESI-MS after purification. 
 
After reaction of the Wang resin 40, with 2-nitro-aniline, the first substituent was introduced 
by alkylation of the carbamate 41. After reduction of the nitro group in 42, the acylation with 
varying Fmoc-amino acids was carried out to yield 44. The intermediate, 45, was cleaved 
from the resin and cyclized at elevated temperature to yield the benzimidazole 46. The last 
step was the cleavage of the Fmoc protecting group to give the desired EMC120B12 
analogues (BE (1-15), Scheme 1, Table 6). 
All compounds (Table 6) were characterized by HPLC-MS and 1H-NMR, (example shown in 
Figure 18).  
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Figure 18. Characterization of compound BE10 by HPLC-MS (214 nm) and 1H-NMR (400 MHz). 
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4.4. Indoles 
The indole structure has been referred to as “privileged structure” due to its presence in 
natural products, indole is part of the essential amino acid tryptophan and a key structural 
component of value in pharmaceuticals. [88, 89] In medicinal chemistry, indole belongs to the 
top five commonly used heterocycles, among them, thiazoles, benzimidazoles, tetrazoles and 
imidazoles. 
The interest in the use of indole derivatives as bioactive molecules against several disorders in 
the human body was recently boosted by their activities against cancer cells and microbes. 
[90,91] 
The indole core has seven positions that can be substituted. Position 3, located in the pyrrole 
ring is the most frequented substituted position followed by position 5 (located in the phenyl 
ring) and position 2 (also, located in pyrrole ring) (Figure 19). [85]  
A) 
 
B) 
 
Figure 19. A) Preferred substitution patterns. B) Pharmaceuticals containing indole structure. 
 
A closer look reveals that indoles tend to be more often disubstituted than monosubstituted. 
Trisubstituted indoles are as frequent as disubstituted indoles.  
For example, Figure 19, part B shows some of the pharmaceutical drugs containing the indole 
scaffold. All of them but Pindolol (53) and Zafirlukas (52) are disubstituted, while Pindolol is 
monosubtituted and Zafirlukas is trisubstituted. 
In conclusion, disubstituted compounds with indole core were synthesized for investigation of 
potential antifungal activity. 
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4.4.1. Synthesis of substituted indoles 
The indole compounds were synthesized as it is described in Scheme 2. The approach started 
by the synthesis of the intermediate β-aminoketoester (54), which was reacted with 2-
iodoaniline and CuI as a catalyst of the reaction to give the indole 55. Intermediate compound 
55 was obtained from compound 55 by acidic cleavage of the Boc-protecting group and 
purified by precipitation.   
 
 
Scheme 2. Planned synthesis of the indole analogues of EMC120B12. 
 
The deprotected amino group of 55a (65 % yield, 98 % pure) was reprotected (56) and the 
activation of the carbxy group was achieved by using N,O-dimethylhydroxylamine 
(Weinreb’s amine) in THF for 18 h to yield compound 57. All variations of the Grignard 
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reaction failed for the generation of compound 58 and consequently, the final product 78. 
Therefore it was decided to change the synthesis route (Scheme 3) by amidation of 56 with 
different amines using ethyl cyano(hydroxyimino)acetate (Oxyma Pure) and EDC 
hydrochloride as coupling reagents to give the product 59. Finally, the deprotection of the 
amino group and the further purification yielded compounds IN-(1-7) (Table 7). 
 
Scheme 3. Final synthetic route for indole compounds (Table 7). 
 
Table 7. Synthesized compounds with an indole scaffold core.  
Compound R Yield (%) Purity (%)* 
IN1 3-Chloro-phenyl 85 94 
IN2 3-Fluoro-phenyl 66 95 
IN3 Phenyl 82 98 
IN4 4-Chloro-phenyl 76 93 
IN5 4-Fluoro-phenyl 26 96 
IN6 2,4-Dichloro-phenyl 77 95 
IN7 3,5-DifluoroPhenyl 74 89 
*Purities were determined by HPLC-MS (214 nm) after purification 
 
A selection of compounds was characterized by HPLC-MS and 1H-NMR and further tested 
for antifungal activity (Figure 20 and 21). 
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Figure 20. HPLC-MS analysis of indole 55a 
 
 
 
Figure 21. HPLC-MS of one of the final indole compounds synthesized, IN1. 
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4.5. Triazoles 
Triazoles are used as pharmaceuticals as well as for plant protection in agriculture. The core is 
a five-membered ring with three nitrogens. Two isomers are possible, either 1,2,3- or 1,2,4-
triazole. 
 
A) 
 
B) 
 
Figure 22. A) Preferred substitution patterns. B) Pharmaceuticals and fungicides containing triazole structure.  
 
The 1,2,4-triazole ring and its tautomer differ in the position of the hydrogen (position 1 or 
position 4). The nomenclature serves to address this subject as for example: Fluconazole, 
which its IUPAC named is: 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1yl)propan-2-ol. 
The N-monosubstituted 1,2,4-triazole seems to be the most common structure over the 
disubstituted and trisubstituted triazole in most of the drugs (Figure 22). [92]  
 
4.5.1. Synthesis of substituted triazoles 
A number of synthetic methods have been investigated to generate the 1,2,4-triazole ring of 
interest.  
The main objective has been to mimic the EMC120B12 structure by modification of the 
scaffold. The synthesis proposed here is a two-step reaction (Scheme 4), which starts with the 
formation of N-protected α-amino acid hydrazide 68 by addition of ethyl chloroformate 
(ECF) at low temperature for 1 h to N-protected α-amino acid. Et3N·HCl was filtered off and 
then hydrazine hydrate was added at low temperature and warmed up to room temperature, 
the desired N-protected α-amino acid hydrazide 68 was obtained. The second step was the 
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addition of dimethyl formamide dimethyl acetal at 50 ºC for 1 h and the selected primary 
amine in HOAc and 50ºC to achieve the triazole molecule 69. The acidolytic deprotection of 
the amino group yielded compounds TR-(1-8). All compounds were purified and 
characterized by HPLC-MS (Table 8). 
 
 
Scheme 4. Synthesis of triazole compounds. 
 
Table 8. List of substituted triazoles.  
Compound R’ R’’ Yield (%) Purity (%)* 
TR1 iPr 3-Chloro-phenyl 65 97 
TR2 Propyl 3-Chloro-phenyl 87 97 
TR3 Propyl 3-Fluoro-phenyl 88 98 
TR4 3-Methylthioethyl 3-Chloro-phenyl 89 94 
TR5 iBu 3-Fluoro-phenyl 71 95 
TR6 iPr Phenyl 54 93 
TR7 iPr 4-Chloro-phenyl 77 97 
TR8 Methyl 4-Fluoro-phenyl 85 96 
*Purities were determined by HPLC-MS (214 nm). 
 
Selected compounds were characterized by 1H-NMR and tested for antifungal activity (Figure 
23). 
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Figure 23. HPLC-MS (214 nm) analysis of triazole compound TR1. 
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4.6. Imidazo[1,2-a]pyridines and imidazo[1,2-a]pyrimidines 
The two bicyclic systems contain an imidazole core and occur in numerous natural products 
and pharmaceuticals. Among the imidazole core derivatives, the most important ones are the 
imidazo[1,2-a]pyridine and the imidazo[1,2-a]pyrimidine. The imidazo[1,2-a]pyridine 
derivatives show a wide range of biological activities such as antifungal, anti-inflammatory, 
antitumor, anticancer or antiviral. [93, 94]  
The main difference between these two ring systems is the six membered ring connected to 
the imidazole moiety which in one case is a pyridine and the other a pyrimidine (Figure 24). 
 
 
Figure 24. Structure of imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine respectively. 
 
Positions 2 and 3, located in the imidazole ring, are the most substituted positions. However, 
the positions 5 to 8 of the pyridine moiety can be substituted as well (Figure 25, A). Not very 
common is the substitution of the imidazole nitrogen in position 1. 
 
A) 
 
B) 
 
Figure 25. A) Preferred substitution patterns. B) Pharmaceuticals containing the imidazo[1,2-a]pyridine 
structure. 
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Examples in Figure 25, B, Alpidem (Sanofi-Aventis, (70)), Zolpidem (71) and Necopidem 
(72) are trisubstituted in positions 2, 3 and 6, while Saripidem (73) is disubstituted at 
positions 2 and 3. The GABAA modulator drug, DS-1 (74), is tetrasubstituted in positions 2, 3 
and 6, and additionally in position 8 (phenyl ring).  
 
4.6.1. Synthesis of imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine 
These structures were designed by scaffold hopping to match the EMC120B12 molecule, as 
closely as possible. 
Both compounds, ImPn1 and ImPm1 were synthesized following the same route. The 
differing step was the addition of 2-aminopyridine for ImPn1 and pyrimidin-2-amine for 
ImPm1 to the α-bromo-amino-β-ketoester 75. 
Tert-butyl β-ketoester (54) was obtained from valine. The bromination of (54) by N-
bromosuccinimide in MeOH at very low temperature yielded 75.  
2-Aminopyridine and 2-aminopyrimidine were added in parallel to obtain the imidazo[1,2-
a]pyridine (76) and imidazo[1,2-a]pyrimidine (77) respectively (Scheme 5 and 6). 
Deprotection of the amino group under acidolytic conditions yielded compounds ImPn1 and 
ImPm1 in reasonable yields (Table 9).  
 
 
Scheme 5. Synthesis of imidazo[1,2-a]pyridine. 
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Scheme 6. Synthesis of the imidazo[1,2-a]pyrimidine. 
 
Table 9. Purities and yields of ImPn1 and ImPm1.  
Compound Yield (%) Purity (%)* 
ImPn1 72 84 
ImPm1 56 61 
*Purities were determined by HPLC-MS (214 nm) after purification. 
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4.7. Study of antifungal activity 
4.7.1. Objective 
The objective of this part was to investigate the biological effect of the new heterocyclic 
compounds against Candida species. Several biological assays were carried out and most of 
the assays have been previously used for the investigation of peptides (Section A). Only the 
dose-response assay and the proteomic analysis were described because these assays are not 
described so far. The following assays have been carried out: high-throughput screening, 
dose-response assay (IC50 and CC50), determination of the minimum inhibitory concentration 
(MIC), evaluation of the antifungal activity of all compounds against clinical isolates of 
Candida species and the proteomic study for two of the most active compounds. 
 
B.4.7.2. High-throughput screening (HTS)  
The screening was carried out at the same conditions as described in “3.6. High-throughput 
screening (HTS)” in Section A for peptide compounds.  
 
B.4.7.2.1. Results for benzimidazole drivatives 
 
Figure 26.  Graphic representation of the screening showing the cell viability of benzimidazole compounds at 10 
µM. All compounds over 40 % cell viability were further studied. BE (2, 4, 6, 7, 9, 10, 11 and 15). 
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4.7.2.2. Results for indole derivatives 
 
Figure 27.  Graphic representation of the screening showing the cell viability of indole compounds at 10 µM. 
 
4.7.2.3. Results for triazole derivatives 
 
Figure 28.  Graphic representation of the screening showing the cell viability of triazole compounds at 10 µM.  
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4.7.2.4. Results for imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine 
 
Figure 29.  Graphic representation of the screening showing the cell viability of both imidazo[1,2-a]pyridine and 
imidazo[1,2-a]pyrimidine compounds at 10 µM.  
 
4.7.3. Inhibitory and cytotoxicity assay 
A dose-response curve was determined to describe the relationship between the drug 
treatment response and drug dose (concentration).  
From the dose-response assay carried out, IC50 (half maximal inhibitory concentration) and 
CC50 (half maximal cytotoxicity concentration) were calculated only for the positive control 
EMC120B12, and analogues BE2, BE4, BE6, BE7, BE9, BE10 and BE11.  
We considered that a compound was active when the cell viability of HeLa cells was high 
(over 80 %) at the lowest concentration (2 μM). All compounds with high cell viability at 2 
μM, were considered as non active compounds and therefore, their IC50 and CC50 were not 
studied. 
Initially, a dose-response assay was carried out in a range of concentration 250 – 2 (μM). The 
results from that first assay encouraged investigating the compounds in a second dose-
response assay at lower concentrations (4 – 0.03125 μM). The objective of this repetition was 
to calculate their IC50 and CC50. To confirm those results a software program was used 
(OriginPro9) fitting the Hill equation, a sigmoidal dose-response curve (Table 26). 
The experimental conditions for those assays were the following: 
- Inhibitory concentration: HeLa cells (50 μl; 10.000 cells/well) + C. albicans (50 μl; 50 CFU) 
+ 100 μl of compound in a 96 well plate. 
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- Cytotoxicity concentration: HeLa cells (50 μl; 10.000 cells/well) + 100 μl compound in a 96 
well plate.  
 
4.7.3.1. Results 
 Inhibitory concentration EMC120B12:  
 
Figure 30. Graphic representation of dose-response assay for EMC120B12 to calculate the 50 % inhibitory 
concentration. A) Range of concentration: 250 – 2 μM. B) Range of concentration: 4 – 0.03125 μM. 
 
 
Table 10. Cell viability (%) at different concentrations during inhibitory assay for EMC120B12. 
 
Inhibitory dose-response 
EMC120B12 
Concentration (μM) % Cell viability Concentration (μM) % Cell viability 
250 4 4 74 
125 23 2 67 
62.5 44 1 36 
31.25 46 0.5 18 
15 73 0.25 8 
7.8 84 0.125 4 
4 77 0.0625 6 
2 92 0.03125 3 
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 Cytotoxicity concentration EMC120B12: 
 
Figure 31. Graphic representation of dose-response assay for EMC120B12 to calculate the 50 % cytotoxicity 
concentration. Range of concentration: 250 – 2 μM. 
 
Table 11. Cell viability (%) at different concentrations during cytotoxicity assay. 
 
Cytotoxicity dose-response 
EMC120B12 
Concentration (μM) % Cell viability 
250 4 
125 58 
62.5 69 
31.25 88 
15 82 
7.8 80 
4 93 
2 93 
 
EMC120B12 showed over 50 % cell viability at 2 μM but it was toxic to HeLa cells between 
125 – 250 μM. 
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 Inhibitory concentration BE2: 
 
Figure 32. Graphic representation of dose-response assay for BE2 to calculate the 50 % inhibitory 
concentration. A) Range of concentration: 250 – 2 μM. B) Range of concentration: 4 – 0.03125 μM.  
 
Table 12. Cell viability (%) at different concentrations during inhibitory assay for BE2. 
 
Inhibitory dose-response 
BE2 
Concentration (μM) % Cell viability Concentration (μM) % Cell viability 
250 4 4 82 
125 60 2 74 
62.5 29 1 60 
31.25 44 0.5 19 
15 75 0.25 3 
7.8 90 0.125 4 
4 94 0.0625 1 
2 98 0.03125 5 
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 Cytotoxicity concentration BE2: 
 
Figure 33. Graphic representation of dose-response assay for BE2 to calculate the 50 % cytotoxicity 
concentration. C) Range of concentration: 250 – 2 μM. 
 
Table 13. Cell viability (%) at different concentrations during cytotoxicity assay for BE2. 
 
Cytotoxicity dose-response 
BE2 
Concentration (μM) % Cell viability 
250 2 
125 62 
62.5 87 
31.25 89 
15 96 
7.8 88 
4 80 
2 91 
 
BE2 showed similar results as EMC120B12, as it was active over 50 % cell viability at 2 μM 
but toxic to HeLa cells between 125 – 250 μM. 
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 Inhibitory concentration BE4: 
 
Figure 34. Graphic representation of dose-response assay for BE4 to calculate the 50 % inhibitory 
concentration. Range of concentration: 250 – 2 μM 
 
Table 14. Cell viability (%) at different concentrations during inhibitory assay for BE4. 
 
Inhibitory dose-response 
BE4 
Concentration (μM) % Cell viability 
250 53 
125 67 
62.5 80 
31.25 80 
15 74 
7.8 27 
4 22 
2 7 
 
 
 Cytotoxicity concentration BE4: 
 
Figure 35. Graphic representation of dose-response assay for BE4 to calculate the 50 % cytotoxicity 
concentration. Range of concentration: 250 – 2 μM. 
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Table 15. Cell viability (%) at different concentrations during cytotoxicity assay for BE4. 
 
Cytotoxicity dose-response 
BE4 
Concentration (μM) % Cell viability 
250 68 
125 90 
62.5 77 
31.25 92 
15 95 
7.8 79 
4 83 
2 91 
 
BE4 showed over 50 % cell viability at 15 μM but it showed to be not toxic to HeLa cells at 
any concentration used. Its IC50 was not calculated. 
 
 Inhibitory concentration BE6: 
 
Figure 36. Graphic representation of dose-response assay for BE6 to calculate the 50 % inhibitory 
concentration. Range of concentration: 250 – 2 μM. 
 
Table 16. Cell viability (%) at different concentrations during inhibitory assay for BE6. 
 
Inhibitory dose-response 
BE6 
Concentration (μM) % Cell viability 
250 58 
125 70 
62.5 73 
31.25 48 
15 26 
7.8 22 
4 5 
2 8 
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 Cytotoxicity concentration BE6: 
 
Figure 37. Graphic representation of dose-response assay for BE6 to calculate the 50 % cytotoxicity 
concentration. Range of concentration: 250 – 2 μM. 
 
Table 17. Cell viability (%) at different concentrations during cytotoxicity assay for BE6. 
 
Cytotoxicity dose-response 
BE6 
Concentration (μM) % Cell viability 
250 81 
125 81 
62.5 77 
31.25 78 
15 76 
7.8 82 
4 91 
2 94 
 
BE6 showed over 50 % cell viability at 62.5 μM but, like BE4, it showed no toxicity to HeLa 
cells at any concentration used. Its IC50 was not calculated. 
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 Inhibitory concentration BE7: 
 
Figure 38. Graphic representation of dose-response assay for BE7 to calculate the 50 % inhibitory 
concentration. Range of concentration: 250 – 2 μM. 
 
Table 18. Cell viability (%) at different concentrations during inhibitory assay for BE7. 
 
Inhibitory dose-response 
BE7 
Concentration (μM) % Cell viability 
250 14 
125 6 
62.5 39 
31.25 71 
15 73 
7.8 79 
4 65 
2 26 
 
 
 Cytotoxicity concentration BE7: 
 
Figure 39. Graphic representation of dose-response assay for BE7 to calculate the 50 % cytotoxicity 
concentration. Range of concentration: 250 – 2 μM. 
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Table 19. Cell viability (%) at different concentrations during cytotoxicity assay for BE7. 
 
Cytotoxicity dose-response 
BE7 
Concentration (μM) % Cell viability 
250 4 
125 55 
62.5 75 
31.25 78 
15 77 
7.8 81 
4 86 
2 96 
 
BE7 showed over 50 % cell viability at 4 μM but at higher concentration the cell viability 
decreased. It was toxic to HeLa cells between 125 – 250 μM. Its IC50 was not calculated. 
 
 Inhibitory concentration BE9: 
 
Figure 40. Graphic representation of dose-response assay for BE9 to calculate the 50 % inhibitory 
concentration. A) Range of concentration: 250 – 2 μM. B) Range of concentration: 4 – 0.03125 μM.  
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Table 20. Cell viability (%) at different concentrations during inhibitory assay for BE9. 
 
Inhibitory dose-response 
BE9 
Concentration (μM) % Cell viability Concentration (μM) % Cell viability 
250 38 4 74 
125 40 2 98 
62.5 45 1 99 
31.25 73 0.5 98 
15 76 0.25 53 
7.8 84 0.125 24 
4 88 0.0625 9 
2 98 0.03125 4 
 
 Cytotoxicity concentration BE9: 
 
Figure 41. Graphic representation of dose-response assay for BE9 to calculate the 50 % cytotoxicity 
concentration. C) Range of concentration: 250 – 2 μM. 
 
Table 21. Cell viability (%) at different concentrations during cytotoxicity assay for BE9. 
 
Cytotoxicity dose-response 
BE9 
Concentration (μM) % Cell viability 
250 4 
125 8 
62.5 74 
31.25 72 
15 69 
7.8 79 
4 87 
2 93 
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BE9 showed over 50 % cell viability at 0.25 μM and toxicity towards HeLa cells between 
62.5 and 125 μM. 
 
 Inhibitory concentration BE10: 
 
Figure 42. Graphic representation of dose-response assay for BE10 to calculate the 50 % inhibitory 
concentration. A) Range of concentration: 250 – 2 μM. B) Range of concentration: 4 – 0.03125 μM.  
 
Table 22. Cell viability (%) at different concentrations during inhibitory assay for BE10. 
 
Inhibitory dose-response 
BE10 
Concentration (μM) % Cell viability Concentration (μM) % Cell viability 
250 3 4 76 
125 66 2 77 
62.5 59 1 78 
31.25 58 0.5 77 
15 77 0.25 65 
7.8 84 0.125 21 
4 86 0.0625 10 
2 93 0.03125 3 
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 Cytotoxicity concentration BE10: 
 
Figure 43. Graphic representation of dose-response assay for BE10 to calculate the 50 % cytotoxicity 
concentration. C) Range of concentration: 250 – 2 μM. 
 
Table 23. Cell viability (%) at different concentrations during cytotoxicity assay for BE10. 
 
Cytotoxicity dose-response 
BE10 
Concentration (μM) % Cell viability 
250 2 
125 58 
62.5 67 
31.25 73 
15 72 
7.8 80 
4 89 
2 98 
 
BE10 showed over 50 % cell viability at 0.25 μM and toxicity towards HeLa cells between 
125 – 250 μM. 
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 Inhibitory concentration BE11: 
 
Figure 44. Graphic representation of dose-response assay for BE11 to calculate the 50 % inhibitory 
concentration. A) Range of concentration: 250 – 2 μM. B) Range of concentration: 4 – 0.03125 μM.  
 
 
Table 24. Cell viability (%) at different concentrations during inhibitory assay for BE11. 
 
Inhibitory dose-response 
BE11 
Concentration (μM) % Cell viability Concentration (μM) % Cell viability 
250 3 4 88 
125 31 2 89 
62.5 74 1 87 
31.25 61 0.5 57 
15 59 0.25 12 
7.8 81 0.125 10 
4 85 0.0625 5 
2 89 0.03125 6 
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 Cytotoxicity concentration BE11: 
 
Figure 45. Graphic representation of dose-response assay for BE11 to calculate the 50 % cytotoxicity 
concentration. C) Range of concentration: 250 – 2 μM. 
 
 
Table 25. Cell viability (%) at different concentrations during cytotoxicity assay for BE11. 
 
Cytotoxicity dose-response 
BE11 
Concentration (μM) % Cell viability 
250 4 
125 52 
62.5 61 
31.25 72 
15 72 
7.8 74 
4 87 
2 96 
 
BE11 showed over 50 % cell viability at 0.5 μM and toxicity towards HeLa cells between 
62.5 and 125 μM. 
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4.7.3.2. IC50 and CC50 calculation  
The software program OriginPro9, fitting Hill equation, was used to obtain the IC50 and CC50. 
The Hill equation is a general equation for a dose-response curve that shows the response as a 
function of the logarithm of concentration (Figure 46), being X the logarithm of agonist 
concentration and Y the response. 
A)                                                                                 B) 
 
Figure 46. Dose-response curve before and after fitting Hill equation (A and B, respectively). B) Three 
logarithm curves: discontinuous line curve corresponds to a Hill slope over 1; discontinuous dot curve 
corresponds to a Hill slope less than 1 and the last curve remain, corresponds to a Hill equation equal to 1.  
 
 
Figure 47. Hill equation 
 
The variable bottom is the Y value at the bottom plateau and the variable top is the Y value at 
the top plateau (Figure 46). EC50 corresponds to X value when the response is halfway 
between bottom and top and its LogEC50 is the logarithm of the EC50. The Hill slope 
describes the steepness of the curve. This variable, also called slope factor or Hill coefficient, 
can be positive, negative or standard. The standard sigmoid dose-response curve has a Hill 
slope of 1, while if it is positive, the curve increases as X increases and the curve is steeper 
(discontinuous curve). On the opposite, when it is negative, the curve decreases as X 
increases and the curve is shallower (discontinuous dot curve) (Figure 46, B). [95 - 96]  
In the next table, values are summarized based on the IC50 and CC50 obtained from the dose-
response curve fitting Hill equation. 
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Table 26. IC50 and CC50 of all active benzimidazole compounds. CI refers to confidence interval and SI to 
selectivity index.  
 
Compound IC50 (μM) 95 % CI CC50 (μM) 95 % CI SI 
EMC120B12 0.971 0.877 – 1.253 105.12 98.37 – 139.29 108.26 
BE2 0.861 0.778 – 0.959 129.32 107.15 – 162.14 150.20 
BE9 0.233 0.208 – 0.266 64.91 61.59 – 76.16 278.58 
BE10 0.194 0.176 – 0.218 201.31 124.22 – 249.48 1037.68 
BE11 0.472 0.434 – 0.515 124.76 102.57 – 162.82 264.32 
 
The selectivity index (SI) shown in Table 26 is the comparison of the amount of the drug 
inhibiting fungal replication effect to the amount that induces cell death and defined as the 
ratio between CC50 and IC50. The higher this index is, the more antifungal activity with 
minimal cell cytotoxicity is induced. The confidence interval (CI) consists of an interval that 
contains the valid value of the corresponding parameter. In this assay carried out, our CI was 
95 % confident and the value of our parameter was within our confidence interval. [97] 
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4.7.4. Minimum inhibitory concentration (MIC) 
4.7.4.1. Results 
 
 
 
Positive control 
EMC120B12 
 
 
 
   
 
 
Figure 48. Results extracted from MIC assay. Voriconazole was used as a positive control and EMC120B12 was 
used to compare with its analogues BE9, BE10 and BE11. Yellow corresponds to C. albicans SC5314; Green 
corresponds to C. glabrata ATCC2001; Pink corresponds to C. parapsilosis ATCC22019 and purple 
corresponds to C. krusei ATCC6258.  
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Figure 49. Results extracted from MIC assay. Yellow corresponds to C. albicans SC5314; Green corresponds to 
C. glabrata ATCC2001; Pink corresponds to C. parapsilosis ATCC22019 and purple corresponds to C. krusei 
ATCC6258.  
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Figure 50. Results extracted from MIC assay. Yellow corresponds to C. albicans SC5314; Green corresponds to 
C. glabrata ATCC2001; Pink corresponds to C. parapsilosis ATCC22019 and purple corresponds to C. krusei 
ATCC6258.  
 
4.7.5.  Screening of clinical Candida spp isolates 
Only the compounds that showed growth inhibition during the MIC analysis for all four 
Candida species were evaluated for further screening. Those one corresponded to 
EMC120B12, BE2, BE6, BE7, BE9, BE10 and BE11.  
BE4 was not further studied due to restricted availability of compound. 
To investigate the activity on the effect for all four Candida species, the concentrations used 
were: 
➢ 8 μg/ml for EMC120B12, BE2, BE6, BE7 and BE11.  
➢ 4 μg/ml for BE10.  
➢ 2 μg/ml for BE9. 
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4.7.5.1. Results 
The results of the screening of clinical Candida spp isolates were summarized in Table 27 
specifying the grade of growth of the fungi with the active compound. 
 
Table 27. Summarized results for the growth of the fungal cells with the compounds at their MIC concentration. 
Bright green colour indicates that the growth of the fungi was less than 10 % and therefore, almost full inhibition 
of the fungi growth with the presence of the compound. Pale green colour indicates that the growth of the fungi 
was between 10-30 %. Skin colour indicates that the growth of the fungi was between 30-40 % and the pale skin 
colour indicates that the growth of fungi was between 40-50 %. The other green colour collects the other 
different Candida species and corresponding to the growth of the fungi between 0-50 %. 
 
 
 
 
 
 
 
 
 
 
 
 
Fungi& C.&albicans(Isolates& C.(glabrata(Isolates& C.(parapsilosis(isolates& C.(krusei&isolates& Other&species&
Heterocycles& " " " " "
EMC120B12&
[8&ug/mL]&
Very&strong&effect& Very&strong&effect& Strong&effect& Strong&effect&
Most&of&the&species:&
C.(lusitaniae(
C.(kefyr(
C.(tropicalis(
BE2&
[8&ug/mL]&
&
Very&strong&effect& Strong&effect& Strong&effect& Poor&effect&
Some&species:&
C.(lusitaniae(
C.(tropicalis(
C.(kefyr(
BE6&
[8&ug/mL]&
&
Very&strong&effect& Strong&effect& Poor&effect& Very&poor&effect&
Some&species:&
C.(kefyr(
C.(lusitaniae(
BE7&
[8&ug/mL]&
&
Very&strong&effect& Strong&effect& Strong&effect& Poor&effect&
Some&species:&
C.(lusitaniae(
C.(kefyr(
C.(tropicalis(
BE9&
[2&ug/mL]&
&
Very&strong&effect& Very&strong&effect& Very&strong&effect& Poor&effect,&only&lab&strain&
Most&of&the&species:&
C.(lusitaniae(
C.(kefyr(
C.(tropicalis(
C.(lipoly5ka(
BE10&
[4&ug/mL]&
&
Very&strong&effect& Very&strong&effect& Very&strong&effect& Very&poor&effect&
Most&of&the&species:&
C.(lusitaniae(
C.(kefyr(
C.(tropicalis(
C.(lipoly5ka(
BE11&
[8&ug/mL]&
&
Very&strong&effect& Very&strong&effect& Very&strong&effect& Poor&effect&
Most&of&the&species:&
C.(lusitaniae(
C.(kefyr(
C.(tropicalis(
C.(lipoly5ka(
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4.7.6. Proteomic study  
4.7.6.1. Objective 
This chemical part was separated from antifungal screening section due to its differences in 
the procedure and objective. In a previous genome study, EMC120B12 was evidenced to 
target the ergosterol pathway by showing 15 genes involved in the ergosterol biosynthesis  out 
of 38 upregulated. EMC120B12 had also an impact on gene products localized in the cell 
surface, the cell wall and the plasma membrane. [26] Therefore, the main objective in this 
section was to carry out the quantitative proteomic4 study of Candida albicans cells grown in 
the absence and presence of EMC120B12 and BE10 (Figure 51) and the comparison or 
resemblance of the genomic study performed previously in presence of EMC120B12. 
Two experimental conditions were selected for comparison of differential abundance of 
proteins in Candida albicans: 
➢ Condition A: C. albicans cells were grown in medium RPMI for 3 h with an O.D = 
0.4 
➢ Condition B: C. albicans cells were grown in medium RPMI for 3 h with an O.D = 
0.4 and in the presence of compounds EMC120B12 and BE10 at their IC50 
concentrations previously determined: 0.75 and 0.19 µM respectively. 
 
 
Figure 51. Structures of the compounds tested against Candida albicans. 
 
4.7.6.2. Introduction  
In order to understand cellular processes, proteomics can be useful tool. Its applications varies 
from large-scale comprehensive study of a specific proteome, including information on 
protein abundances or their variations and modifications, along with their interacting partners 
 
4 This analysis was carried out at Universidad Complutense de Madrid, Madrid. 
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and networks. [98] A proteome is a set of proteins produced in an organism or system. The 
proteome is not constant, it differs from cell to cell, it changes over time and also when the 
cell or organism undergoes stress. [99] 
Proteomics can provide significant biological information for many biological problems, such 
as:  
1 - Which proteins interact with a particular protein of interest. 
2 - Which proteins are localized to a subcellular compartment. 
3 - Which proteins are involved in a biological process.  
 
4.7.6.3. Unique challenges for proteomics compared to genomics 
The biggest conceptual challenge inherent in proteomics lies in the proteome's increased 
degree of complexity compared to the genome. [100, 101] For example: 
• One gene can encode more than one protein: the human genome contains about 21,000 
protein-encoding genes, but the total number of proteins in human cells is estimated to 
be between 250,000 to one million.  
• Proteins are dynamic: proteins are continually undergoing changes such as binding to 
the cell membrane, partnering with other proteins to form complexes, or undergoing 
synthesis, post-translational modifications and degradation. The genome, on the other 
hand, is relatively static.  
• Proteins exist in a wide range of concentrations in the cells: this makes it extremely 
difficult to detect the low abundance proteins in a complex biological matrix.  
 
4.7.6.4. Tools used for proteomics 
Mass spectrometry (MS) is the most important technology to detect and quantify proteins in a 
complex biological matrix. MS methods are very precise, distinguishing proteins that differ in 
composition by a single hydrogen atom. Despite its potential, common technologies are not 
yet capable of separating the complex protein mixtures from human biospecimens. Additional 
technologies such as organelle or protein fractionation or affinity capture have been 
developed to reduce the complexity of protein mixtures from biospecimens. Furthermore, the 
continuous improvement of the sensitivity of instrumentation for detection and quantification 
of proteins can be expected. [102 - 103] 
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4.7.6.5. Fluorescence microscopy  
The viability of Candida albicans was visualized by fluorescence microscopy technique [104] 
in the presence of EMC120B12 and BE10 at different times. The two common dyes used for 
this study were dihydrorhodamine (DHR) and propidium iodide (PI).  The viability was 
determined using an optical-to-electronic coupling system that recorded how the cell scattered 
incident laser light and emitted fluorescence. 
Those two dyes were selected because DHR is an uncharged and nonfluorescent reactive 
oxygen species (ROS+) indicator that can passively diffuse across membranes where it is 
oxidized to cationic rhodamine 123, which localizes in the mitochondria. Its fluorescence 
wavelength is 596 nm and exhibits green fluorescence. The PI is an intercalating agent that 
binds to DNA and its detection wavelength is 617 nm exhibiting a red fluorescence. 
The study was carried out with: 
➢ C.albicans SC5314 with H2O2 and MeOH as a positive control for ROS+ and PI, 
respectively  
➢ C.albicans SC5314 + EMC120B12  
➢ C.albicans SC5314 + BE10  
Incubation times used were 1.5 h, 3 h, 4.5 h and 6 h at 37 ºC (180 rpm) and the test 
compounds were dissolved in RMPI medium with 1 % of DMSO. The viability of the cells 
was observed by fluorescence microscopy. In total, two biological replicates were performed.  
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▪ Incubation time 1.5 h 
                         SC5314                                   SC + EMC120B12                           SC + BE10 
    
Figure 52. Images obtained from fluorescence microscopy for SC5314, SC5314 + EMC120B12 and SC5314 + 
BE10 after 1.5 h. Differential interference contrast (DIC) and merge, as the combination of ROS+ and PI results.  
 
At 1.5 h, ROS+ and PI detection was not visualized for any of the two compounds.  
▪ Incubation time 3 h 
                             SC5314                               SC + EMC120B12                            SC + BE10 
 
Figure 53. Images obtained from fluorescence microscopy for SC5314, SC5314 + EMC120B12 and SC5314 + 
BE10 after 3 h. Differential interference contrast (DIC) and merge as the combination of ROS+ and PI results.  
 
After 3 h, the sample treated with compound BE10 showed ROS+ production much stronger 
than the one caused by compound EMC120B12. PI was not visualized. 
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▪ Incubation time 4.5 h 
                          SC5314                                 SC + EMC120B12                             SC + BE10 
    
Figure 54. Images obtained from fluorescence microscopy for SC5314, SC5314 + EMC120B12 and SC5314 + 
BE10 after 4.5 h. Differential interference contrast (DIC) and merge as the combination of ROS+ and PI images.  
 
At 4.5 h, the cells suffered from stress, as ROS+ was visualized. The cells with BE10 started 
to show some PI.  
▪ Incubation time 6 h 
                               SC5314                              SC + EMC120B12                             SC + BE10 
 
Figure 55. Images obtained from fluorescence microscopy for SC5314, SC5314 + EMC120B12 and SC5314 + 
BE10 after 6 h. Differential interference contrast (DIC) and merge as the combination of ROS+ and PI images.  
 
After 6 h, ROS+ and PI detection was clearly visualized for both compounds in higher levels 
than the other time points. 
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This assay confirmed that the compounds EMC120B12 and BE10 produced stress to 
Candida albicans SC5314 cells at 3, 4.5 and 6 h. At 1.5 h the ROS+ effect was not visualized, 
suggesting that there was still no stress produced for the compounds at that early time. At time 
point 6 h, it was possible to observe some death cells which was the reason why this time was 
discarded to perform the proteomic assay. Between 3 and 4.5 h, there was not much difference 
in cell stress, so to assure better visualization with the study, both time points 3 h and 4.5 h 
were selected for the proteomic assay.  
 
4.7.6.6. Protein extraction 
To study the proteins involved in some processes, it is necessary to extract the proteins. To 
carry out the assay, cells were mixed with glass beads and were disrupted in the bead beater, 
to disrupt the cell wall. The debris cells were removed by centrifugation and the protein lysate 
was stored at -80 °C.  
The samples were later quantified and visualized by Bradford method and SDS-PAGE gel, 
respectively.  
 
4.7.6.7. Protein quantification 
The protein quantification is done by Bradford method, which it is used specially to determine 
the protein content of cell fractions and assessing protein concentrations for gel 
electrophoresis. 
The assay is based on the observation that the absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to protein 
occurs. Both hydrophobic and ionic interactions stabilize the anionic form of the dye, causing 
a visible colour change. The assay is useful since the extinction coefficient of a dye-albumin 
complex solution is constant over a 10-fold concentration range. [105] 
To determine the concentration of protein of the cell fractions in our samples, a standard curve 
was performed with bovine serum albumin (BSA) and proteins with known concentrations. 
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Figure 56. Standard curve with BSA. The regression equation was used to determine the protein concentration 
of the Candida albicans lysates (y = absorbance and x = concentration of the sample). 
 
Table 28. Results obtained after Bradford method to quantify the concentration of proteins. There are 3 
replicates for each of the samples. Absorbance values were given and the amount of proteins and concentrations 
were calculated. 
 
The values of total concentration (μg/μl) obtained by Bradford method allowed to perform a 
SDS-PAGE.  
 
 
 
 Samples  Absorbance Protein amount 
(µg) 
Concentration 
(µg/µl) 
3
 h
 
SC5314  0.502 
0.538 
0.528 
9.791 
10.514 
10.313 
1.958 
2.102 
2.062 
SC5314 + EMC120B12 0.403 
0.55 
0.503 
7.803 
10.755 
9.811 
1.560 
2.151 
1.962 
SC5314 + BE10 0.457 
0.471 
0.519 
8.887 
9.168 
10.132 
1.777 
1.833 
2.026 
4
.5
 h
 
SC5314  0.539 
0.563 
0.497 
10.534 
11.016 
9.690 
2.160 
2.203 
1.938 
SC5314 + EMC120B12 0.620 
0.629 
0.563 
12.160 
12.341 
11.016 
2.432 
2.468 
2.203 
SC5314 + BE10 0.555 
0.631 
0.541 
10.855 
12.381 
10.574 
2.171 
2.476 
2.114 
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4.7.6.8. Protein pattern visualization by SDS-PAGE 
Sodium dodecyl sulfate – polyacrylamide gel electrophoresis is a standard technique [106] used 
to separate proteins. This method uses a discontinuous polyacrylamide gel as a support 
medium and sodium dodecyl sulfate (SDS) to denature the proteins. Protein separation by 
SDS-PAGE can be used to estimate relative molecular mass, to determine the relative 
abundance of major proteins in a sample, and to determine the distribution of proteins. [107] 
The SDS is an anionic detergent, meaning that when dissolved its molecules have a net 
negative charge within a wide pH range. The protein chain binds amounts of SDS in 
proportion to its relative molecular mass. The negative charges on SDS destroy most of the 
complex structure of proteins, and are strongly attracted toward an anode (positively-charged 
electrode) in an electric field. [108, 109] 
Polyacrylamide gel restrains larger molecules from migrating as fast as smaller molecules, 
due to the charge/mass ratio, which it is nearly the same among SDS-denatured polypeptides. 
The final separation of proteins is dependent almost entirely on the differences in their 
relative molecular masses.  
Two parallel gels were run with SC5314, SC5314 + EMC120B12 and SC5314 + BE10 of 
each one, three biological replicates for the time points 3 and 4.5 h.  
        
Figure 57. Protein pattern of Candida albicans cells grown with EMC120B12 and BE-10 and their replicates 
(up to 3) during 3 h in RPMI medium (complemented with FBS 10%).   
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Figure 58. Protein pattern of Candida albicans cells grown with EMC120B12 and BE-10 and their replicates 
(up to 3) during 4.5 h in RPMI medium (complemented with FBS 10%).   
 
The protein separation did not indicate much difference between the cells EMC120B12 and 
BE10 neither after 3 h nor 4.5 h. Therefore, Candida albicans cells were treated with 
EMC120B12 for 3 h to carry out the proteomic study.  
 
4.7.6.9. Protein digestion 
After protein quantification, the samples were treated for protein digestion. Serine protease 
trypsin was employed as it cuts enzymatically peptide chains mainly at the carboxy side of the 
basic amino acids lysine or arginine. The generated peptides are in the preferred mass range 
for MS sequencing producing information-rich, easily interpretable peptide fragmentation 
mass spectra (Scheme 7). [110, 111]  
 
Scheme 7. a) After obtaining the protein concentration, the samples were digested. b) The digested samples were 
labelled with TMTsixplex Isobaric Mass Tagging Kit. c) The samples were injected to mass spectrometer: Q-
TRAP, LTQ and MALDI-TOF/TOF. 
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4.7.6.10. Peptide labelling with TMT 
A mass tag was introduced to the samples after digestion to later quantify the proteins with 
differences in abundance in the mass spectra. 
Tandem mass tag (TMT) (Figure 59) is a chemical label used for mass spectrometry (MS)-
based quantification and identification of biological macromolecules such as proteins, 
peptides or nucleic acids. [112] 
 
 
Figure 59. Structure of TMT label reagent 
 
 
4.7.6.11. Results 
The proteomic results are summarized in tables below and in comparison with the genomic 
study. Statistical significance was adjusted to a P value ≤0,05. Proteins were classified 
according to their gene and role. Highlighted in green are those that correlate with the gene. 
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Table 29. a Fold expression from the previous genomic study. b fold expression from this proteomic study. c 
correlation between the genomic and proteomic studies: Yes means that proteins were correlated to the genes; No 
was the opposite and (/) means that some correlation was found between proteomic and genomic study at P value  
≥0,05. Positive values: up-regulated; negative values: down-regulated. 
  Gene Fold expression 
(genomic)a 
Adjusted P 
value 
Fold expression 
(proteomic)b 
Adjusted P 
value 
Correlationc 
R
o
le
 i
n
 e
rg
o
st
er
o
l 
b
io
sy
n
th
es
is
 
ERG1 4,34 0,000108 - - No 
ERG10 2,6 0,000948 1,617 9,99999E-07 Yes 
ERG11 8,41 0,000000 - - No 
ERG13 4,91 0,000000 0,574 1,1E-05 Yes 
ERG2 2,96 0,006752 - - No 
ERG24 3,32 0,001618 - - No 
ERG25 2,64 0,000193 - - No 
ERG251 4,66 0,000024 - - No 
ERG26 2,09 0,000224 - - No 
ERG3 6,95 0,000036 - - No 
ERG4 3,08 0,001412 - - No 
ERG5 3,05 0,000069 - - No 
ERG6 11,36 0,000028 1,31 9,99999E-07 Yes 
ERG9 2,57 0,0022424 - - No 
UPC2 3,47 0,000159 - - No 
 
 
Table 30. Proteomic results. a fold expression from the previous genomic study. b fold expression from this 
proteomic study. c correlation between the genomic and proteomic studies: Yes means that proteins were 
correlated to the genes; No was the opposite and (/) means that some correlation was found between proteomic 
and genomic study at P value  ≥0,05. Positive values: up-regulated; negative values: down-regulated. 
  Gene Fold expression 
(genomic)a 
Adjusted P 
value 
Fold expression 
(proteomic)b 
Adjusted P 
value 
Correlationc 
S
h
o
w
 c
h
a
n
g
ed
 t
ra
n
sc
ri
p
t 
le
v
el
s 
in
 r
es
p
o
n
se
 t
o
 
a
n
ti
m
y
co
ti
cs
 
CHT2 -3,90 0,000036 -0,704 0,000589504 Yes 
CRH11 2,02 0,006851 1,255 9,99999E-07 Yes 
CSH1 2,12 0,005475 - - No 
DDR48 13,84 0,000000 1,808 9,99999E-07 Yes 
FRP1 2,01 0,00082 - - No 
FTH1 2,03 0,000472 - - No 
HYR1 2,72 0,003792 0,591 0,000964819 Yes 
NHP6A -2,04 0,001358 -0,303 0,023372078 / 
orf19.6688 -3,39 0,000147 - - No 
orf19.7504 2,46 0,007689 - - No 
orf19.3475 -2,20 0,046451 -0,481 7,80E-05 Yes 
orf19.3737 2,15 0,024789 - - No 
PGA7 2,46 0,000472 - - No 
PHR2 4,38 0,000116 0,103 0,444555445 / 
POL30 -2,00 0,006851 0,064 0,622377622 No 
RTA2 4,18 0,000312 - - No 
RTA3 3,18 0,030754 - - No 
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Table 31. Proteomic results. a fold expression from the previous genomic study. b fold expression from this 
proteomic study. c correlation between the genomic and proteomic studies: Yes means that proteins were 
correlated to the genes; No was the opposite and (/) means that some correlation was found between proteomic 
and genomic study at P value  ≥0,05. Positive values: up-regulated; negative values: down-regulated. 
  Gene Fold expression 
(genomic)a 
Adjusted P 
value 
Fold expression 
(proteomic)b 
Adjusted P 
value 
Correlationc 
O
th
er
 f
u
n
ct
io
n
s 
 
ARO10 -5,25 0,000734 -0,203 0,13643178 / 
CDG1 -2,04 0,000281 -0,493 0,011528734 Yes 
CHA1 -2,46 0,000734 - - No 
CIP1 -2,19 0,026148 - - No 
FAV1 2,04 0,028653 - - No 
GCV2 -2,18 0,010078 -0,312 0,015921852 / 
HSP31 -2,83 0,016218 - - No 
HTA2 -2,32 0,003792 -0,108 0,441558442 / 
MAL2 -2,96 0,000166 -0,658 9,99999E-07 Yes 
PGA23 5,5 0,000009 - - No 
PGA26 -3,35 0,00026 - - No 
PST3 2,1 0,000028 0,95 9,99999E-07 Yes 
RBT1 -2,63 0,000177 - - No 
SET3 3,19 0,000005 - - No 
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4.8. DISCUSSION – SECTION B 
➢ Chemistry: EMC120B12 analogues were synthesized following a method of parallel 
solid phase organic synthesis based on published procedures. Based on the main 
benzimidazole hit, EMC120B12, compound collections with different cores have 
been designed and synthesized using the scaffold hopping approach. The triazole 
compounds were successfully obtained in a two steps reaction in good yields. For the 
synthesis of the indole family it was necessary to modify the route because the 
described Grignard step was unsuccessful to obtain intermediate compound (58). The 
new modified route, starting from compound (56), allowed the synthesis of indole 
compounds (IN1 – IN7). 
It was observed, that the functional groups of the most active compounds were similar.  
In position 2, all four active EMC120B12 analogues contained a linear alkyl group 
substituent (Figure 60). Other analogues with a phenyl or methyl substituent (e.g. 
BE14 or BE1) in that same position were not active. In position 1, the presence of 
fluoro or chloro in meta position in the phenyl substituent of the benzimidazole had 
stronger effect compared to analogues where the fluoro or chloro substituents were 
located in para position of the phenyl substituent (e.g. BE3 or BE4).  
 
 
Figure 60. Structures and substitutions of the most active benzimidazole analogues. 
 
The analogues with a phenyl ring in position 1 with no heteroatom substitution were 
active only if the substituent in position 2 was a linear alkyl group (e.g. BE15 vs 
BE14). BE15 was designed to compare the effect of the heteroatom in the phenyl 
substituent on the antifungal activity (BE9 or BE10). The results showed that the 
linear alkyl substituent had more effect on the antifungal activity than the phenyl 
substituent, as BE15 showed higher cell viability than BE9.  
All compounds synthesized in this work were tested against Candida species and their 
antifungal activity was evaluated. 
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➢ High-throughput screening:  
- Benzimidazole: The investigation of 9 out of 16 benzimidazole compounds exhibited 
strong antifungal activity with more than 40 % of HeLa cell viability at 10 μM. All 
those hits with high percentage of HeLa cell viability were retested and evaluated in a 
dose-response assay in order to determine their IC50, and CC50.  
- Indole: The results from the screening at 10 μM revealed that none of the indole 
compounds tested was active against Candida albicans. The HeLa cell viability did 
not reach the 20 % cut off.  
- Triazole: These compounds showed no antifungal activity against Candida albicans 
at 10 μM. The HeLa cell viability was very low (20 %). 
- The two compounds, imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine were not 
active against Candida albicans at 10 μM. 
Indoles, triazole and imidazole compounds were not further studied. 
 
➢ Dose-response assay: This assay confirmed the high antifungal activity of all 
benzimidazole compounds previously screened at the high-throughput screening at 10 
µM (HTS).  
During the first dose-response assay with concentrations from 250 to 2 μM, positive 
control EMC120B12, BE2, BE9, BE10 and BE11 showed very high antifungal 
activity at the lowest concentration used (2 μM). BE4, BE6 and BE7 were not active 
enough (their cell viability was lower than 50 %) to be considered as an active 
compound and therefore, their IC50 was not calculated. 
To calculate the IC50 for the active ones, a second dose-response assay was carried out 
but in that case, the range of concentration was decreased (4 – 0.0.3125 μM). At 
concentration of 0.5 and 1 μM, EMC120B12 and BE2 reduced the growth of Candida 
albicans, but below those concentrations, the effect was marginal. BE9, BE10 were 
very active at 0.25 and 0.5 μM with cell viability over 70 %. BE11 was also active but 
at higher concentrations, 0.5 and 1 μM.  
A dose-response cytotoxicity assay was performed and it was observed that at lowest 
concentrations, the active compounds: EMC120B12, BE2, BE9, BE10 and BE11 
were not toxic to HeLa cells except at highest concentrations (125 – 250 μM).    
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Table 32. Summary of % cell viability values for the compounds tested in an inhibitory and cytotoxicity 
dose-response assay. Only lowest concentrations can be visualized; (4, 2 and 1 μM) for the inhibitory 
assay and (7.8, 4 and 2 μM) for the cytotoxicity assay. 
 
 Dose-Response 
Inhibitory Cytotoxicity 
Concentration (μM) Concentration (μM) 
4 2 1 7.8 4 2 
C
o
m
p
o
u
n
d
s 
(%
 c
el
l 
v
ia
b
il
it
y
) 
EMC120B12 74 67 36 80 93 93 
BE2 82 74 60 88 80 91 
BE4 22 7 - 79 83 91 
BE6 5 8 - 82 91 94 
BE7 65 26 - 81 86 96 
BE9 74 98 99 79 87 93 
BE10 76 77 78 80 89 98 
BE11 88 89 87 74 87 96 
 
BE9, though, showed higher cytotoxicity, killing HeLa cells at 62.5 μM. 
All their IC50 and CC50 were calculated (Table 26). 
For compounds BE4, BE6 and BE7, unlike the dose-response assay for inhibitory 
concentration, they showed to be not toxic to HeLa cells even at the highest 
concentration (125 – 250 μM). Either way, their IC50 and CC50 were not calculated. 
 
➢ Minimum inhibitory concentration (MIC): All four compounds (EMC120B12, 
BE9, BE10 and BE11) were thoroughly active against the C. albicans SC5314 at low 
concentration. Compared to EMC120B12, the three analogues, BE(9-11), were more 
active (0.5 – 1 μM). 
For the remaining fungi species, all four compounds inhibited the growth at the 
highest concentration (10 μM). BE9 and BE10 showed slightly more activity, shown 
by inhibiting the growth at concentrations (< 10 μM) (Table 33). 
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Table 33. Summary of the results from minimum inhibitory concentration (MIC) of compounds 
EMC120B12, BE9, BE10 and BE11 and for all Candida species tested. 
 
 Candida 
species 
albicans 
SC5314 
glabrata 
ATCC2001 
parapsilosis 
ATCC22019 
krusei 
ATCC6258 
C
o
m
p
o
u
n
d
s 
EMC120B12 
0.4 µg/ml (1.27 
µM) 
0.35 µg/ml 
(1.11 µM) 
2 µg/ml (6.3 µM) 
BE9 
0.075 µg/ml 
(0.24 µM) 
0.125 µg/ml 
(0.40 µM) 
0.195 µg/ml 
(0.62 µM) 
0.8 µg/ml 
(2.55 µM) 
BE10 
0.090 µg/ml 
(0.3 µM) 
0.230 µg/ml 
(0.77 µM) 
0.47 µg/ml 
(1.58 µM) 
0.90 µg/ml 
(3.02 µM) 
BE11 
0.095 µg/ml 
(0.27 µM) 
0.45 µg/ml 
(1.30 µM) 
0.37 µg/ml 
(1.06 µM) 
1.98 µg/ml 
(5.73 µM) 
 
BE2, BE 4, BE6 and BE7 were active against all Candida species too, but at higher 
concentrations. Analogue BE2 was more active at lowest concentration in comparison to 
other analogues (Table 34). 
 
Table 34. Summary of the results from minimum inhibitory concentration (MIC) of compounds BE2, BE6 
and BE7 for all Candida species tested. 
 
 Candida 
species 
albicans SC5314 glabrata 
ATCC2001 
parapsilosis 
ATCC22019 
krusei 
ATCC6258 
C
o
m
p
o
u
n
d
s 
BE2 
0.97 µg/ml (3.1 
µM) 
2.0 µg/ml 
(6.37 µM) 
3.2 µg/ml 
(10.2 µM) 
4.2 µg/ml 
(13.4 µM) 
BE4 
6.5 µg/ml 
(21.8 µM) 
10 µg/ml (33.6 µM) 
BE6 
1.97 µg/ml (6.32 
µM) 
1.5 µg/ml 
(4.81 µM) 
6.2 µg/ml (19.90 µM) 
BE7 
1.98 µg/ml (7.08 
µM) 
1.0 µg/ml 
(3.58 µM) 
6.2 µg/ml (22.2 µM) 
 
The compounds (BE1, BE3 and BE14) were active at highest concentrations and active 
against one Candida species (Table 35). BE1 and BE3 were active for C.albicans and 
BE14 for C.glabrata. 
 
Table 35: Summary of the results from minimum inhibitory concentration (MIC) of compounds BE1, BE3 
and BE14 for all Candida species tested. 
 
 Candida 
species 
albicans SC5314 glabrata 
ATCC2001 
parapsilosis 
ATCC22019 
krusei 
ATCC6258 
C
o
m
p
o
u
n
d
s BE1 
3.5 µg/ml (12.3 
µM) 
11.5 µg/ml 
(40.2 µM) 
No activity 
BE3 
3.7 µg/ml (13.74 
µM) 
No activity 
BE14 
No activity 1.98 µg/ml 
(6.05 µM) 
No activity 
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➢ Screening of clinical Candida spp isolates: Only the active compounds in the MIC 
study were screened further against clinical Candida spp isolates. The selected 
compounds were EMC120B12, BE (2, 6, 7, 9, 10 and 11) and they were tested with 
the minimum inhibitory concentration obtained from the previous study.  
As it had been shown in the previous assays, BE9, BE10 and BE11 gave a very strong 
response against C. albicans, C. glabrata and C. parapsilosis, inhibiting the growth of 
these fungi over 90 %. However, for C. krusei, the inhibition was in the range of 50-70 
%. EMC120B12 was also very active and gave good activity against all Candida 
species, inhibiting from 70 to 90 % of the fungi growth.  
BE2 and BE7 showed inhibition over 90 % only for C. albicans and an inhibition 
between 70-90 % for C. glabrata and C. parapsilosis. For C. krusei, the inhibition was 
lower, between 60-70 %.  BE6 gave very good activity against C. albicans and C. 
glabrata (inhibition of the fungi growth between 70-90 %). However, for C. 
parapsilosis and C. krusei, the inhibition was not exceeding the 70 %.  
For all the compounds studied, the antifungal activity against other Candida species, 
like C. lusitaniae or C. tropicalis, among others, was very good, inhibiting at least 
over the 60 % of the fungi growth.  
 
➢ Proteomic study: This assay was only carried out for the hit compounds 
EMC120B12 and BE10. BE10 was selected because it was the most active compound 
so far, even showing better results than the compound we used as a control, 
EMC120B12. The initial hit (EMC120B12) was chosen for the final proteomic study, 
to compare and/or confirm with the genomic study already published. [26] BE10 was 
treated but was not further studied. 
The results showed that some proteins were upregulated correlating with the genes in 
the genomic study. Those genes were assigned to play a role in the ergosterol 
biosynthesis, to show changed transcript levels in response to antimycotics and also 
related to other functions.  
This first approach showed the presence of other proteins linked to the ergosterol 
biosynthesis that were not upregulated in the genomic study.  
In conclusion of this study, gene ontology (GO) analysis revealed that most of the 
upregulated genes (q value ≤0,05) were localized to the cell surface, the cell wall and 
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the plasma membrane, indicating that EMC120B12 has strong impact on membrane 
and cell wall biosynthesis similar to some azoles like fluconazole.  
On the opposite, the GO analysis for the downregulated genes, showed that they were 
located in the extracellular region and nucleus, indicating that EMC120B12 does not 
have much effect on that regions.  
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5. CONCLUSIONS 
In an effort to discover novel antifungal compounds, different peptides and heterocycles have 
been designed, synthesized and tested for their antifungal activity. 
The conclusions reached in this thesis are the following: 
➢ Several analogues of the peptide LL-37 have been designed and synthesized using 
automated solid phase peptide synthesis (SPPS). These novel peptides have been studied 
for their antifungal activity. During the primary high-throughput screening (HTS) assay, 
only analogue KS-30-NH2 (16) gave remarkable activity. Minimum inhibitory 
concentration (MIC) for the LL-37 peptide analogues was also determined. However, 
(16) did not show any positive results, whereas, analogues FK-13, (31) and (32) did 
inhibit the growth of all four Candida species used at the highest concentration.  
➢ Several benzimidazole analogues from a previous hit, EMC120B12 [20, 26] were 
synthesized following the procedures established at EMC microcollections GmbH. Eight 
out of fifteen benzimidazole analogues exhibited a very high activity against Candida 
albicans, C.glabrata, C.parapsilosis and C.krusei.  From those active analogues BE10 
was the most active with an IC50 below 0.5 μM and a CC50 over 200 μM; BE9 and B11 
were also active, but their IC50 and CC50 were higher than 0.5 μM and less than 200 μM, 
respectively and therefore, less active than BE10. 
BE15 showed activity at the HTS with cell viability almost 70 % at 10 μM.  
Different analogues of EMC120B12 were synthesized by scaffold hopping. The 
heterocycles chosen were indole, triazole, imidazo[1,2-a]pyridine and imidazo[1,2-
a]pyrimidine. All compounds were synthesized in solution phase combinatorial organic 
chemistry. Unfortunately, these compounds synthesized were not active against Candida 
albicans in the high-throughput screening (HTS) at 10 μM. 
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6. EXPERIMENTAL PART 
6.1. Section A – Chemical synthesis of LL-37 analogues 
6.1.1. Materials  
6.1.1.1. Solvents 
All solvents used were reagent grade quality unless stated otherwise and used without further 
purification. Milli-Q water with a resistively superior to 18.2 MΩ/cm. 
 
Solvent Supplier 
ACN  VWR 
CHCl3 Acros Organics 
DCM VWR 
DMF peptide synthesis quality Acros Organics 
Et2O technical grade VWR 
EtOH Merck 
H2O (Milli-Q) Millipore 
MeOH quality HPLC VWR 
 
6.1.1.2. Reagents 
Reagent  Supplier 
Rink amide resin 
Rapp Polymere 
Chloro-(2’-chloro)trityl resin 
Ac2O 98 % Fluka 
DIPEA 99 % Acros Organics 
DIC 99 % Iris Biotech 
DMSO 99 % Acros Organics 
HCl 37% VWR 
HOBt  Biosolve 
NMP 99.5 % Acros Organics 
Ninhydrin Merck 
OxymaPure® Iris Biotech 
Piperidine Acros Organics 
TCTU 98 % Iris Biotech 
TFA technical grade VWR 
TFA HPLC grade Fisher 
TIS Acros Organics 
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6.1.1.3. Instruments 
Instrument Supplier and Model 
Centrifuge Hettich, Universal 30 F  
Lyophilizer Christ, Alpha 1-4, Pump Edwards RV5 
Sonicator Elma, Transsonic T780/H 
Spectrometer Pharmacia Biotech, Ultrospec ® 2000 
Peptide Synthesizer Syro II, Dual robotic arm 
RP-HPLC-MS Waters  Alliance 2795, Chromolith 
FastGradient RP-18e 50 x 2 mm column, 
2489 UV detector and 3100 mass detector 
HPLC-Analytical Gilson 322 UV/VIS detector (ReproSil-Pur 
ODS (3-5 µm, 50 x 4.6 mm) column 
HPLC-Preparative Gilson 151 UV/VIS detector; reprospher 
C18 (5µm, 120 x 20 mm) column 
Balance Acculab Sartorius group 
Ohaus, Analytical Plus 
 
6.1.2. Methods 
6.1.2.1. Qualitative ninhydrin assay 
This assay allows the qualitative evaluation of the efficiency of the couplings of the amino 
acids in solid phase peptide synthesis, by means of the colorimetric detection of the free 
amino groups in the N-terminal side of the growing peptide chain. In the assay three different 
reagents are used:  
 - Solution I: KCN solution (0.66 mg in 1 mL H20) in pyridine (w/v) 
 - Solution II: Ninhydrin in ethanol (w/v) (2 g in 40 mL) 
 - Solution III: Phenol in ethanol (w/v) (30 g in 7.5 mL) 
The assay is carried out by introducing, in an Eppendorf cup, some clean and dry beads with 
the polymer-bound peptide. One drop of each solution is added, and the mixture is heated at 
105 °C for 3 min. Developing blue colour of the solution and the resin indicates the presence 
of free primary amino groups (positive assay), therefore the coupling is incomplete and it is 
necessary to repeat the coupling, while a yellow colour indicates the absence of free primary 
amino groups (negative assay) (reaction in Scheme 8). 
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Scheme 8: Reaction between a free primary amino group and the ninhydrin to yield the blue compound 
Ruhemann’s purple (positive assay). 
 
6.1.2.2. Fmoc quantification 
This quantification is used to determine the loading of the resin with the first amino acid. The 
resin (50 mg, 15 µmol) was swollen with DCM and DMF (3 mL). After filtration, Et3N in 
DMF (3 mL) was added for 2 min and discarded. To the resin, the first amino acid (3 eq) of 
the sequence was dissolved in DMF (1 mL) and added, together with DIPEA (3 eq). The 
reactor with resin was left for 1.5 h with continuous shaking.  
The resin was washed with DMF, MeOH, DCM and Et2O (3x). Before quantifying the 
amount of Fmoc, the resin was very well dried and put into the desiccator for 2 h or overnight.  
A resin sample (8-12 mg) was transferred to a falcon tube and DMF with piperidine (30 %) 
(500 µl) was added and left for 45 min with constant shaking.  
That solution (100 µl) was transferred to a new falcon tube and DMF (5900 µl) was added.  
The absorbance was obtained using a spectrometer and the concentration was calculated 
based on Lambert-Beer formula: 
 
𝐴 =  𝜀 𝑙 𝑐  →   𝑐 =  𝐴/ɛ 𝑙 
A = absorbance; ɛ = molar attenuation coefficient; c = concentration and l = path-length 
 
The blank used corresponded to DMF with piperidine (30 %) (100 µl), diluted in DMF (5900 
µl). This procedure was repeated 3 times. 
The optimal concentration corresponded to >0.45 mmol/g. If the test showed concentration 
below 0.45 mmol/g, the coupling of the amino acid was repeated.  
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6.1.2.3. Solid Phase Peptide Synthesis (SPPS) 
The peptides were synthesized using a fully automated parallel synthesizer (Syro II, 
MultiSynTech, Bochum, Germany) with a reactor block of 96 positions and a software 
control computer, which not only controls the instrument functions, but also calculates all 
amounts and volumes of required amino acids and reagents. The reactors were filled with 
Rink Amide or trityl resins (depending on the desired C-terminal end; Rink Amide for a C-
terminal amide or trityl for a C-terminal carboxylic acid). The protocol used was previously 
optimized at EMC microcollections GmbH. The peptide synthesis was controlled during the 
synthesis after cleavage by HPLC-MS. 5 mg of resins were collected and a mixture of 
TFA/Reagent K*/H2O (80:15:5, v/v) (500 μL) was added for 1 h at room temperature. (* The 
Reagent K composition is: phenol (5 %, v/v), thioanisole (5 %, v/v) and 1,2-ethanedithiol 
(5 %, v/v). 
The peptide was precipitated with Et2O (1 mL) and the solvent was decanted. This procedure 
was repeated 3 times. The peptide was then lyophilized with tBuOH/H2O (4:1, v/v) and 
analysed with HPLC-MS (214 nm).   
 
Protocol for coupling - deprotection and washing steps: 
Coupling Steps Text/Command 
1 Flush needle (DMF) for 1 cycle 
2 Fill reactor with 40 µL reagent 3M DIPEA 
3 Fill reactor with 60 µL reagent 3M DIC 
4 Fill reactor with 200 µL building block (amino acid residue) 
5 Hold for 50 min 
6 Empty for 0.50 min into waste container  
7 Wash system: DMF; 1 cycle 300 µL 0.50 min into waste container 
8 Fill reactor with 40 µL reagent 3M DIPEA 
9 Fill reactor with 100 µL building block (amino acid residue) 
10 Fill reactor with 200 µL reagent TCTU 
11 Hold for 60 min 
12 Empty for 0.50 min into waste container  
13 Wash system: DMF; 4 cycles 300 Fill reactor with 200 µL 0.50 min into waste 
container 
14 Fill reactor with 200 µL reagent: Piperidine 30% 
15 Hold for 5.0 min 
16 Empty for 0.50 min into waste container 
17 Wash system: DMF; 1 cycle 300 µL 0.50 min into waste container 
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18 Fill reactor with 300 µL reagent: Piperidine 30 % 
19 Hold for 10 min 
20 Empty for 0.50 min into waste container 
21 Wash system: DMF; 8 cycles 300 µL 0.50 min into waste container 
 
6.1.2.4. Cleavage and deprotection 
The reactors were taken out from the Syro II synthesizer after synthesis and washed several 
times with diethyl ether. Cleavage and full deprotection of the linear peptides from the resin 
was carried out by acidolysis with a mixture of TFA/triisopropylsilane/H2O (95:3:2, v/v) or 
TFA/Reagent K/H2O (80:15:5, v/v) for 90 min. After cleavage, the resin was filtered off and 
washed with pure TFA and DCM (1 mL, 2x). The combined filtrates were evaporated to a 
reduced volume under a gentle stream of air. The crude peptide was precipitated with cold 
Et2O (3 mL), centrifuged for 3 min (4800 rpm) and separated by decantation from the 
supernatant. This procedure was repeated 3 times. Before purification, the compounds were 
dissolved in a mixture of tBuOH/H2O (4:1, v/v) and lyophilized.  
 
6.1.2.5. RP-HPLC purification 
The peptides were purified by preparative RP-HPLC. The instrument used was a Gilson 151 
UV/VIS detector; Reprospher C18 (5µm, 120 x 20 mm) column, and the detection was 
carried out at 214 nm. The samples were eluted at a flow rate of 10 mL/min using linear 
gradients (0 – 100 %; 45 – 100 %; 30 – 75 %) of the following solvents: 
A: H2O – 0.1 % TFA 
B: ACN – 0.1 % TFA 
The peptides were characterized by analytical RP-HPLC and RP-HPLC-MS. The columns 
used were a ReproSil-Pur ODS (3-5 µm, 50 x 4.6 mm) for analytical HPLC and Chromolith 
FastGradient RP-18e (50 x 2 mm) with a 2489 UV detector and 3100 mass detector. The 
detections were carried out at 214 nm for both HPLCs.  
The samples were eluted at a flow rate of 1 mL/min using linear gradient of the following 
solvents: 
For RP-HPLC:                                        For RP-HPLC-MS: 
A: H2O – 0.1 % TFA                              C: H2O – 0.1 % FA 
B: ACN – 0.1 % TFA                             D: ACN – 0.1 % FA 
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6.2. SECTION B – Chemical synthesis of heterocyclic compounds   
6.2.1. Materials 
6.2.1.1. Solvents 
All solvents used were reagent grade quality unless stated otherwise and used without further 
purification. Milli-Q water with a resistively superior to 18.2 MΩ/cm. 
 
Solvent Supplier 
ACN 99 % VWR 
CHCl3 Acros Organics 
DCM technical grade VWR 
Dioxane Acros Organics 
DMF technical grade Acros Organics 
DMSO 99 % Acros Organics 
Et2O technical grade VWR 
EtOH 99 % Merck 
H2O (Milli-Q) Millipore 
MeOH 98 % VWR 
THF 99.9 % Acros Organics 
Toluene Fisher 
 
6.2.1.2. Reagents 
All reagents used were of the maximum purity available 
Reagent  Supplier 
Wang resin Rapp Polymere 
2,6-lutidine Fluka 
2-aminopyridine Acros Organics 
2-iodoaniline ChemPur 
3-chlorobenzylamine Alfa Aesar 
3-fluorobenzylamine Aldrich 
4-chlorobenzylamine Acros Organics 
Ac2O Fluka 
Boc2O Acros Organics 
CDI Fluka 
Citric acid Fluka 
Cs2CO3 Fluka 
CuI Riedel-deHaen 
DIPEA Acros Organics 
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DIC Iris Biotech 
DMFDMA Acros Organics 
DSMO Acros Organics 
ECF Fluka 
EDC·HCl Biotech 
Et3N Fisher 
HCl 37% VWR 
Hydrazine hydrate Sigma Aldrich 
HOBt Biosolve 
L-Pro Fluka 
MeNHOMe-HCl Acros Organics 
NaHCO3 Acros Organics 
NBS Acros Organics 
NMP Acros Organics 
Ninhydrin Merck 
Oxyma Pure Sigma Aldrich 
Piperidine Acros Organics 
PyBOP Iris Biotech 
TFA technical grade VWR 
TEA Acros Organics 
TIS Acros Organics 
 
6.2.2. Methods 
6.2.2.1. General procedure for benzimidazoles 
Syntheses of benzimidazoles were carried out by methods of parallel solid phase organic 
synthesis and following the protocol from EMC microcollections GmbH. [20] Activation of 
Wang resin (77) to p-nitrophenyl carbonate Wang resin (40) (Scheme 9) was achieved by 
addition of 4-nitrophenylchloroformate in DCM for 15 h. After washing the resin with DMF, 
MeOH, DCM and Et2O (4x) and drying under high vacuum, 2-nitroaniline in presence of 
NaH was added to give the corresponding 2-nitrophenyl carbamates (41). Alkylation of the 
carbamate with the desired benzyl bromides using lithium tert-butoxide as a base gave the 
alkyl-(2-nitrophenyl) carbamate Wang resin (42). Analysis was done by HPLC-MS after 
cleavage of the intermediate from a small amount of resin (3 mg) (42) by TFA (25 %) in 
DCM . The nitro group was reduced by a solution of 1M of stannous chloride dihydrate in dry 
DMF to afford polymer bound carbamoyl anilines (43). Further acylation of the weakly 
nucleophilic aniline could be achieved most efficiently by PyBrOP mediated activation of N-
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Fmoc-α- amino acids in the presence of DIPEA in NMP. Complete conversion of the anilines 
(44) was determined colorimetrically by treatment of the resin with ninhydrin (Kaiser test).   
Acidolytic cleavage (25 % TFA in DCM) and evaporation of the reagents provided N-Fmoc-
α-amino acid anilides (45). 
The N-α-protected benzimidazol-2-yl-alkylcarbamates (46) were obtained by heating (45) in 
glacial acetic acid at 80 °C for 16 h. Deprotection of the primary amino group by a mixture of 
piperidine/DCM afforded (S)-2-aminoalkyl-benzimidazoles BE(1-15). The purification of the 
benzimidazoles was carried out by column chromatography using a mixture of DCM:MeOH 
(3-5 %) and monitored by TLC.  
 
 
Scheme 9: Reagents and conditions: (a) 1.6 eq pyridine, 10 eq 4-nitrophenylchloroformate in DCM; (b) 3 eq 
NaH, DMF, 2.5 eq nitroaniline, 12h; (c) 5 eq alkylbromide, 8 eq LiOtBu, THF/DMSO (1:1, v/v), 16h; (d) 1M 
SnCl2 in DMF, 16 h; (e) 2.5 eq Fmoc-amino acid, 5 eq DIPEA, 2.5 eq PyBrOP, NMP, 16 h; (f) 25% TFA/DCM, 
1 h; (g) HOAc, 80 °C, 16 h; (h) 5% piperidine, DCM, 2 h. 
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6.2.2.2. Wang resin activation (40)  
 
 
                                                                                                                        
Wang resin (77) (200 mg, 1.28 mmol·g-1) was suspended in DCM (2.1 mL) at 0°C. Pyridine 
(33 µL, 0.40 mmol) and 4-nitrophenylchloroformate (516 mg, 2.56 mmol) were added 
dropwise. The suspension was stirred for 30 min at 0°C and 15 h at room temperature. The 
resin was washed with DMF, MeOH, DCM and Et2O (4x) and dried under high vacuum. 
 
6.2.2.3. Loading of Wang resin (41) 
 
 
                                                                                                                         
2-Nitroaniline (88.4 mg, 0.64 mmol) and a solution of NaH (18.4 mg 0.77 mmol) in DMF 
were added to p-nitrophenyl carbonate Wang resin (200 mg) (40) and stirred at room 
temperature 16 h.  
The solution was washed with DMF until the washing solution was almost colorless. After 
washing, NH4OH (25 % water) in DMF (1.5 mL per 100 mg of resin approximately) was 
added and shaken for 1 h at room temperature.  
The resin (41) was washed with DMF, MeOH, THF, DCM and Et2O (4x) and dried in an 
evacuated desiccator. 
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6.2.2.4. 3-Chlorobenzyl-(2-nitrophenyl)carbamate Wang resin (42) 
 
 
                                                                                                                           
3-Chlorobenzyl bromide (168 µL, 1.28 mmol) was added to a suspension of 2-nitrophenyl-
carbamate Wang resin (41) in a mixture of dry THF and DMSO (3 mL, 1:1, v/v). Lithium 
tert-butoxide (164 mg, 2.04 mmol) was added and the suspension was agitated for 16 h at 
room temperature. The resin was collected by filtration, washed with DMF, MeOH, DCM and 
Et2O (4x) and dried in an evacuated desiccator. 
The intermediate (42) was analyzed using HPLC-MS (214 nm) after cleavage of a small 
amount (5 mg) of the resin with 25% TFA in DCM (1 h) followed by evaporating the 
solvents.  
 
6.2.2.5.  3-Chlorobenzyl-(2-aminophenyl)carbamate Wang resin (43) 
 
 
                                                                                                          
A 1M solution of stannous chloride dihydrate in dry DMF (3 mL) was added to the 3-
chlorobenzyl (2-nitrophenyl)carbamate Wang resin (42) and the suspension was agitated for 
16 h at room temperature. The resin (43) was collected by filtration, washed with DMF, 
MeOH, DCM and Et2O (4x) and dried in high vacuum. The reduction was monitored by 
cleavage of a small amount (5 mg) of the intermediate compound (43) with 25% of TFA in 
DCM (1 h) evaporating the solvents and analyzed by HPLC-MS (214 nm). 
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6.2.2.6. 3-Chlorobenzyl-(2-(Fmoc-L-valylamino)phenyl)carbamate Wang resin (44) 
 
 
                                                                                                           
Fmoc-L-valine (217 mg, 0.64 mmol), N,N-diisopropylethylamine (0.223 mL, 1.28 mmol) and 
PyBrOP (298 mg, 0.64 mmol) were dissolved in dry NMP (1.5 mL) and added to a 
suspension of 3-chlorobenzyl(2-aminophenyl)carbamate Wang resin (43) in dry NMP (2.25 
mL). The suspension was agitated for 16 h in a shaker at room temperature. The resin (44) 
was collected by filtration, washed with DMF, MeOH, DCM and Et2O (4x) and dried in high 
vacuum for at 4.5 h. The complete acylation was proven by chloranil test of a small amount of 
resin (2-5 mg) and it was observed that the resin (in contrast to a non-acylated control sample) 
did not show the typical blue-stained resin beads indicating the conversion of the aniline. 
 
6.2.2.7. (9H-Fluoren-9-yl)methyl (R)-(1-((2-((3-chlorobenzyl)amino)phenyl)amino)-3-
methyl-1-oxobutan-2-yl)carbamate (45) 
 
 
                                                                                                                      
3-Chlorobenzyl(2-(Fmoc-L-valylamino)phenyl)carbamate Wang resin (200 mg) (44) was 
suspended in 25 % TFA in DCM (3.2 mL). The suspension was agitated for 1 h and then 
filtrated. The resin was washed with DCM and MeOH (5 mL, 3x) and all the filtrates were 
combined. Solvents were removed by evaporation and the crude product (45) was lyophilized 
from tert-butylalcohol/water (4:1 v/v) to yield a pale yellow solid. 
Yield: 64 %, C33H32ClN3O3, MW: 554 g/mol  
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6.2.2.8. (9H-Fluoren-9-yl)methyl (S)-(1-(1-(3-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)-2-
methylpropyl)carbamate (46) 
 
 
Compound (45) (74.7 mg, 0.13 mmol) was dissolved in glacial acetic acid (3 mL) and heated 
at 80 °C for 16 h. Solvents were removed by evaporation and the crude product (46) was 
lyophilized from tert-butylalcohol/water (4:1, v/v) to yield a dark oil. 
 
6.2.2.9. (S)-2-(1-Aminoisobutyl)-1-(3-chlorobenzyl)benzimidazole (EMC120B12) 
 
                                                                              
(9H-Fluoren-9-yl)methyl(S)-(1-(1-(3-chlorobenzyl)-1H-benzo[d]imidazol-2-yl)-2-
methylpropyl) carbamate (74.7 mg, 0.14 mmol) (46) was dissolved in DCM (6.1 mL). 
Piperidine (303 µL, 3.03 mmol) was added and the reaction was stirred for 2 h at room 
temperature. Solvents were removed by evaporation and the crude product (EMC120B12) 
was purified by column chromatography (silica gel, 3 % of MeOH in DCM) to yield the pure 
compound. 
Yield: 65 %; brown solid; 97% purity; Rf (3 % MeOH/DCM)= 0.24, C18H20ClN3, MW: 
313.83 g/mol; HPLC-ESI-MS, 214 nm: [M+H]+ = 314 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.66 (d, 3H), 1.22 (d, 3H), 2.95 (m, 1H), 4.22 (d, 1H), 5.42 
(dd, 2H), 6.95-6.90 (m, 2H), 7.32-7.21 (m, 5H), 7.80 (d, 1H). 
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6.2.2.10. EMC120B12 analogues 
(S)-2-(1-Aminoethyl)-1-(4-chlorobenzyl)benzimidazole (BE1) 
 
 
(S)-2-(1-Aminoethyl)-1-(4-chlorobenzyl)benzimidazole (BE1) was synthesized analogously 
to compound EMC120B12. Purification by chromatography on silica gel; MeOH (3 %) in 
DCM. 
Yield: 85 %; Pale brown solid; DCM:MeOH (3 %) Rf = 0.3, C16H16ClN3, MW: 285.78 g/mol, 
purity: 91 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 286 m/z 
1H-NMR (400 MHz, CDCl3) δ 1.55 (d, 3H), 2.36 (m, 1H), 5.27 (dd, 2H), 6.93-6.91 (m, 3H), 
7.26-7.21 (m, 4H), 7.76 (d, 1H). 
 
(S)-2-(1-Aminoisobutyl)-1-(4-chlorobenzyl)benzimidazole (BE2) 
 
 
(S)-2-(1-Aminoisobutyl)-1-(4-chlorobenzyl)benzimidazole (BE2) was synthesized 
analogously to compound EMC120B12. Purification by chromatography on silica gel; MeOH 
(3 %) in DCM. 
Yield: 66 %; Brown solid; MeOH (3 %) in DCM Rf = 0.24, C18H20ClN3, MW: 313.83 g/mol, 
purity: 96 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 314 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.64 (d, 3H), 0.94 (d, 3H), 2.23 (m, 1H), 4.48 (d, 1H), 5.46 
(dd, 2H), 7.02-7.05 (m, 2H), 7.18-7.22 (m, 2H), 7.26-7,3 (m, 3H), 7.68 (d, 1H). 
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(S)-2-(1-Aminoethyl)-1-(4-fluorobenzyl)benzimidazole (BE3) 
 
 
(S)-2-(1-Aminoethyl)-1-(4-fluorobenzyl)benzimidazole (BE3) was synthesized analogously  
to compound EMC120B12. Purification by chromatography on silica gel; MeOH (3 %) in 
DCM. 
Yield: 82 %; Pale brown solid;  MeOH (3 %) in DCM Rf = 0.38, C18H20FN3, MW: 297.38 
g/mol, purity: 91 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 298 m/z.   
1H-NMR (400 MHz, CDCl3) δ 1.42 (d, 3H), 2.66 (m, 1H), 5.45 (dd, 2H), 7.03-6.98 (m, 2H), 
7.13-7.05 (m, 2H), 7.31-7.27 (m, 3H), 7.76 (d, 1H). 
 
(S)-2-(1-Aminoisobutyl)-1-(4-fluorobenzyl)benzimidazole (BE4) 
 
 
(S)-2-(1-Aminoisobutyl)-1-(4-fluorobenzyl)benzimidazole (BE4) was synthesized 
analogously to compound EMC120B12. Purification by chromatography on silica gel; MeOH 
(3 %) in DCM. 
Yield: 76 %; Brown solid; MeOH (3 %) in DCM Rf = 0.25, C16H16FN3, MW: 269.32 g/mol, 
purity: 96 % (HPLC-ESI-MS, 214 nm), [M+H]+= 270 m/z. 
1H-NMR (400 MHz, CDCl3) δ 0.42 (d, 3H), 1.11 (d, 3H), 2.45 (m, 1H), 4.63 (d, 1H), 5.47 
(dd, 2H), 7.24-7.17 (m, 2H), 7.33-7.29 (m, 3H), 7.64-7,57 (m, 2H), 7.79 (d, 1H).   
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(S)-2-(1-Aminoethylindolyl)-1-(3-chlorobenzyl)benzimidazole (BE5) 
 
 
(S)-2-(1-Aminoethylindolyl)-1-(3-chlorobenzyl)benzimidazole (BE5) was synthesized 
analogously to compound EMC120B12. Purification by chromatography on silica gel; MeOH 
(3 %) in DCM. 
 Yield: 25 %; Dark brown solid; MeOH (4 %) in DCM Rf = 0.27, C24H21ClN4, MW: 400.91 
g/mol, purity: 76 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 401 m/z.   
 
 (S)-2-(1-Aminoisopentyl)-1-(3-fluorobenzyl)benzimidazole (BE6) 
 
 
(S)-2-(1-Aminoisopentyl)-1-(3-fluorobenzyl)benzimidazole (BE6) was synthesized 
analogously to compound EMC12012. Purification by chromatography on silica gel; MeOH 
(3 %) in DCM. 
Yield: 77 %; Pale brown solid; MeOH (3 %) in DCM Rf = 0.21, C19H22FN3, MW: 311.41 
g/mol, purity: 97 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 312 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.63 (d, 3H), 0.69 (d, 3H), 1.32 (m, 1H), 1.58 (dd, 2H), 4.36 (t, 
1H), 5.22 (dd, 2H), 6.87-7.03 (m, 2H), 7.13-7.09 (m, 2H), 7.26-7,37 (m, 3H), 7.72 (d, 1H). 
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(S)-2-(1-Aminoisobutyl)-1-(benzyl)benzimidazole (BE7) 
 
 
(S)-2-(1-Aminoisobutyl)-1-(benzyl)benzimidazole (BE7) was synthesized analogously to 
compound EMC120B12. Purification by chromatography on silica gel; MeOH (3 %) in 
DCM. 
Yield: 74 %; Brown solid; MeOH (3 %) in DCM Rf = 0.22, C18H21N3, MW: 279.39 g/mol, 
purity: 81 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 280 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.89 (d, 3H), 1.11 (d, 3H), 2.33 (m, 1H), 4.37 (d, 1H), 5.36 
(dd, 2H), 7.27-7.23 (m, 2H), 7.52-7.31 (m, 6H), 7.61 (d, 1H). 
 
(S)-2-(1-Aminoisopentyl)-1-(3-chlorobenzyl)benzimidazole (BE8) 
 
 
(S)-2-(1-Aminoisopentyl)-1-(3-chlorobenzyl)benzimidazole (BE8) was synthesized 
analogously to compound EMC120B12. Purification by chromatography on silica gel; MeOH 
(3 %) in DCM. 
 Yield: 73 %; Brown solid; MeOH (3 %) in DCM Rf = 0.28, C19H22ClN3, MW: 327.86 g/mol, 
purity: 92 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 328 m/z.  
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(S)-2-(1-Aminobutyl)-1-(3-chlorobenzyl)benzimidazole (BE9) 
 
 
(S)-2-(1-Aminobutyl)-1-(3-chlorobenzyl)benzimidazole (BE9) was synthesized analogously 
to compound EMC120B12. Purification by chromatography on silica gel; MeOH (3.5 %) in 
DCM. 
Yield: 55 %; Pale brown solid; MeOH (3.5 %) in DCM Rf = 0.31, C18H20ClN3, MW: 313.16 
g/mol, purity: 99 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 314 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.74 (t, 3H), 1.27-1.21 (m, 2H), 1.65 (dt, 2H), 4.10 (t, 1H), 
5.47 (dd, 2H), 6.91-6.89 (m, 2H), 7.20-7.16 (m, 2H), 7.48-7.32 (m, 3H), 7.80 (d, 1H). 
 
(S)-2-(1-Aminobutyl)-1-(3-fluorobenzyl)benzimidazole (BE10) 
 
 
(S)-2-(1-Aminobutyl)-1-(3-fluorobenzyl)benzimidazole (BE10) was synthesized analogously 
to compound EMC120B12. Purification by chromatography on silica gel; MeOH (3 %) in 
DCM. 
Yield: 51 %; Pale brown solid; MeOH (3 %) in DCM Rf = 0.24, C18H20FN3, MW: 298 g/mol, 
purity: 95 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 299 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.86 (t, 3H), 1.33-1.21 (m, 2H), 1.80 (dt, 2H), 4.12 (t, 1H), 
5.48 (dd, 2H), 6.80 (dd, 2H), 6.96 (dt, 1H), 7.30-7.20 (m, 4H), 7.78 (d, 1H). 
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(S)-2-(1-Aminomethylthiopropyl)-1-(3-chlorobenzyl)benzimidazole (BE11) 
 
 
(S)-2-(1-Aminomethylthiopropyl)-1-(3-chlorobenzyl)benzimidazole (BE11) was synthesized 
analogously to compound EMC120B12. Purification by chromatography on silica gel; MeOH 
(4 %) in DCM. 
Yield: 31 %; Dark brown solid, MeOH (4 %) in DCM Rf = 0.26, C18H20ClN3S, MW: 345.90 
g/mol, purity: 97 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 346 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.91 (s, 3H), 2.22-2.14 (m, 2H), 2.5 (dt, 2H), 4.51 (t, 1H), 5.46 
(dd, 2H), 6.95 (d, 2H), 7.32-7.21 (m, 5H), 7.79 (d, 1H). 
 
(S)-2-(1-Amino-4-hydroxiphenylethyl)-1-(3-chlorobenzyl)benzimidazole (BE12) 
 
 
(S)-2-(1-Amino-4-hydroxiphenylethyl)-1-(3-chlorobenzyl)benzimidazole (BE12) was 
synthesized analogously to compound EMC120B12. Purification by chromatography on 
silica gel; MeOH (3 %) in DCM. 
Yield: 34 %; Pale brown solid, MeOH (3 %) in DCM Rf = 0.17, C22H20ClN3O, MW: 377.88 
g/mol, purity: 98 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 378 m/z.  
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(S)-2-(1-Aminoethyl)-1-(benzyl)benzimidazole (BE13) 
 
 
(S)-2-(1-Aminoethyl)-1-(benzyl)benzimidazole (BE13) was synthesized analogously to 
compound EMC120B12. Purification by chromatography on silica gel; MeOH (3.5 %) in 
DCM. 
Yield: 86 %; Pale brown solid; MeOH (3.5 %) in DMC Rf = 0.13, C16H17N3, MW: 251.33 
g/mol, purity: 92 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 252 m/z. 
1H-NMR (400 MHz, CDCl3) δ 1.23 (d, 3H), 3.99 (q, 1H), 5.33 (dd, 2H), 7.21-7.17 (m, 2H), 
7.62-7.29 (m, 6H), 7.77 (d, 1H). 
 
(S)-2-(1-Aminobenzylmethyl)-1-(benzyl)benzimidazole (BE14) 
 
 
(S)-2-(1-Aminobenzylmethyl)-1-(benzyl)benzimidazole (BE14) was synthesized analogously 
to compound EMC120B12. Purification by chromatography on silica gel; MeOH (3.5 %) in 
DCM. 
Yield: 46 %; Pale yellow solid; MeOH (3.5 %) in DCM Rf = 0.27, C22H21N3, MW: 327.43 
g/mol, purity: 96 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 328 m/z. 
1H-NMR (400 MHz, CDCl3) δ 3.06 (dd, 2H), 4.28 (t, 1H), 5.21 (dd, 2H), 6.96 (dd, 2H), 7.06 
(dd, 3H), 7.28-7.21 (m, 8H), 7.83 (d, 1H). 
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(S)-2-(1-Aminobutyl)-1-(benzyl)benzimidazole (BE15) 
 
 
(S)-2-(1-Aminobutyl)-1-(benzyl)benzimidazole (BE15) was synthesized analogously to 
compound EMC120B12. Purification by chromatography on silica gel; MeOH (3.5 %) in 
DCM. 
Yield: 73 %; Pale brown solid; MeOH (3.5 %) in DCM Rf = 0.21, C18H21N3, MW: 279.39 
g/mol, purity: 96 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 280 m/z. 
1H-NMR (400 MHz, CDCl3) δ 0.81 (t, 3H), 1.32-1.22 (m, 2H), 1.85 (dt, 2H), 4.21 (t, 1H), 
5.57 (dd, 2H), 7.01 (dd, 2H), 7.33 (dt, 1H), 7.21-7.16 (m, 5H), 7.58 (d, 1H). 
 
6.2.2.11. Boc protection 
Boc2O (0.588 mL, 1.2 eq, 2.56 mmol, 80) and Et3N (0.862 mL, 2.9 eq, 6.2 mmol) were added 
to L-valine (250 mg, 2.13 mmol, 79) in a single-necked, round-bottomed flask, diluted in 
dioxane:H2O (1:1, 10 mL) and the mixture was left stirring for 18 h at room temperature. The 
solution was extracted with petroleum ether and the aqueous phase was cooled on ice and 
carefully acidified to pH = 3 by addition of 10 % citric acid aqueous solution. The organic 
phase was extracted with EtOAc (8 mL, 3x) and the combined extracts were washed with sat. 
NaCl (2x), dried with Na2SO4, filtered and concentrated under reduced pressure to give the 
protected α-amino acid (81) in 83 % yields.  
 
 
 
Scheme 10: Conditions: a) Et3N (2.9 eq), Boc2O (1.2 eq), dioxane:H2O (1:1), 18 h, room temperature 
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6.2.2.11.1. Preparation of 4-Boc-amino-3-ketoester (54) 
CDI (1.1 g, 1.35 eq, 6.2 mmol) was added to a stirred solution of Boc-valine (1 g, 4.6 mmol) 
in THF at room temperature under Ar atmosphere for 40 min. A freshly prepared solution of 
lithium tert-butoxycarbonylmethanide (78) was prepared in parallel by addition of nBuLi 
(16.6 mL, 4.2 eq, 179.8 mmol) with a syringe to a solution of diisopropylamine (6 mL, 42.8 
mmol) in dry THF (8 mL), under argon and cooled to 0 ºC. This mixture was stirred at 0 ºC 
for 10 min and then cooled to -78 ºC. Tert-butyl acetate dissolved in dry THF was added 
dropwise by syringe and the resulting mixture was stirred for 15 min.  
The acyl imidazole solution prepared previously was then added dropwise to the pale yellow 
solution of the lithium enolate at -78 ºC under Ar. The reaction mixture was stirred for 40 min 
and then the reaction was quenched with 1 N HCl (10 mL). After extraction with EtOAc (2x), 
the combined organic extracts were washed with brine (3x), dried over Na2SO4, filtered and 
concentrated by rotary evaporation to provide the Boc-amino-3-ketoester. The crude product 
tert-butyl (S)-4-((tert-butoxycarbonyl)amino)-5-methyl-3-oxohexanoate (54) was purified by 
chromatography on a colum using cyclohexane:EtOAc (4:1) as solvents. Yield: 67 %. 
 
 
Scheme 11: Conditions: a) CDI (1.35 eq), THF, 40 min at room temperature; BuLi (4.2 eq), DIPA (1 eq), TBAc 
(1 eq), under Ar, 40 min, -78 ºC.  
 
6.2.2.12. General procedure for indoles (IN1-IN7) 
A solution of the corresponding β-ketoester intermediate (54) (100 mg, 1 eq, 0.32 mmol) in 
dry DMSO (5 mL) was treated with 2-iodoaniline (69.5 mg, 1 eq, 0.32 mmol), CuI (12 mg, 
0.2 eq, 0.06 mmol), L-Pro (14.6 mg, 0.4 eq, 0.12 mmol) and Cs2CO3 (103.3 mg, 1 eq, 0.32 
mmol) and stirred at 50 °C for 12 h (Scheme 12). The reaction mixture was neutralized with 
1M HCl (8 mL) and extracted with EtOAc (2x). The organic phase was washed with brine 
(3x) and dried over Na2SO4, the solvent was evaporated and the crude material (55) was 
purified by precipitation (Petroleum Ether:EtOAC). After purification, the ester and also Boc 
were cleaved by an acidic mixture composed of TFA/DCM/TIS/H2O (80:20:5:1) for 1 h at 
room temperature to yield the indole intermediate 55a. 55a was again protected, following 
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procedure explained in 6.2.2.11. to obtain the protected indole intermediate (56) in 86 % 
yield. Without any previous purification and in a single-necked, round-bottomed flask, (56) 
(100 mg, 0.3 mmol) was charged with EDC·HCl (63.4 mg, 1.1 eq, 0.33 mmol) and dissolved 
in DCM/DMF (1:1) (5 mL). The colourless solution of the carbodiimide was then stirred at 
room temperature for approximately 20 min to allow complete dissolution of the reactant, 
followed by cooling in an ice bath to 0 °C. Then, the indole intermediate (56) and Oxyma 
(Pure) (47 mg, 1.1 eq, 0.33 mmol) were added to the cold solution of EDC·HCl. Two min 
after the addition of the reactants, the corresponding substituted amine was added to the 
preactivated (56), followed by addition of DIPEA (63 μL, 1.2 eq, 0.57 mmol) and allowed to 
stir in an ice bath for 1 h. To assure a complete coupling, Oxyma and DIPEA were again 
added and the reaction was left overnight at room temperature. After 14-15 h, the solvent was 
removed and the crude oily residue was diluted in chloroform and transferred to a separatory 
funnel. The organic solution was extracted and washed with 1 N HCl, sat. Na2CO3 and 
saturated NaCl. The resulting pale yellow organic fraction was dried over Na2SO4, filtered 
and concentrated by rotary evaporation. The amino group (59) was deprotected with a mixture 
composed of TFA/DCM/TIS/H2O (80:20:5:1). Finally, the crude products (IN(1-7)) were 
purified by column chromatography with DCM:MeOH (4 %) as a eluents. 
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Scheme 12: Conditions: a) CuI (0.2 eq), Cs2CO3 (1 eq), L-Pro (0.4 eq) in dry DMSO, 50 ºC overnight, b) 
Mixture: TFA/DCM/TIS/H2O (80/20/5/1), 1 h, room temperature, c) Boc2O (1 eq), Et3N (2.9 eq), dioxane:H2O 
(1:1), 18 h at room temperature, d) EDC:HCl (1.1 eq), Oxyma Pure (1.1 eq), DCM:DMF (1:1), R-NH2 (1.1 eq), 
DIPEA (1.2 eq), 0 ºC for 1 h, and then overnight at room temperature, e) Mixture: TFA/DCM/TIS/H2O 
(80/20/5/1), 1 h, room temperature. 
 
6.2.2.12.1. Indole analogues 
(S)-2-(Aminoisobutyl)-3-(carboxylic acid)indole (55a) 
 
 
55a 
(S)-2-(Aminoisobutyl)-3-(carboxylic acid)indole (55a) was obtained as described in 
6.1.2.1.4.4. Purified by precipitation EtOAc/Cyclohexane. Yield: 65 %, Brownish oil; 
C13H18N2O2, MW: 234.14 g/mol; purity: 98 % (HPLC-ESI-MS, 214), [M+H]+ = 235 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.86 (d, 3H), 1.03 (d, 3H), 1.24-1.13 (m, 1H), 4.83 (d, 1H), 
7.25-7.20 (m, 2H), 7.50 (d, 1H), 8.05 (d, 1H), 12.27 (s, 1H). 
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(S)-2-(Aminoisobutyl)-3-(N-3-chlorobenzylcarbamoyl)indole (IN1) 
 
 
(S)-2-(Aminoisobutyl)-3-(N-3-chlorobenzylcarbamoyl)indole (IN1) was obtained as 
described in 6.2.2.12. Purification by silica gel chromatography MeOH (3.5 %) in DCM. 
Yield: 85 %; Green oil; MeOH (3.5 %) in DCM; Rf = 0.21, C20H22ClN3O, MW: 355.87 
g/mol; purity: 94 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 356 m/z. 
1H-NMR (400 MHz, CDCl3) δ 0.91 (d, 3H), 1.01 (d, 3H), 1.17-1.11 (m, 1H), 4.66 (d, 1H), 
4.88 (dd, 2H), 7.10-7.06 (m, 2H), 7.22-7.14 (m, 2H), 7.66-7.32 (m, 3H), 7.81 (d, 1H). 
 
 
(S)-2-(Aminoisobutyl)-3-(N-3-fluorobenzylcarbamoyl)indole (IN2) 
 
  
(S)-2-(Aminoisobutyl)-3-(N-3-fluorobenzylcarbamoyl)indole (IN2) was obtained as 
described in 6.2.2.12. Purification by silica gel chromatography MeOH (3.5 %) in DCM. 
Yield: 66 %; Dark green oil; MeOH (3.5 %) in DCM; Rf = 0.15, C20H22FN3O, MW: 339.41 
g/mol; purity: 95 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 340 m/z. 
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(S)-2-(Aminoisobutyl)-3-(N-benzylcarbamoyl)indole (IN3) 
 
  
(S)-2-(Aminoisobutyl)-3-(N-benzylcarbamoyl)indole (IN3) was obtained as described in 
6.2.2.12. Purification by silica gel chromatography MeOH (3.5 %) in DCM. 
Yield: 82 %; Pale green oil; MeOH (3-4 %) in DCM; Rf = 0.37, C20H23N3O, MW: 321.42 
g/mol; purity: 98 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 322 m/z. 
 
(S)-2-(Aminoisobutyl)-3-(N-4-chlorobenzylcarbamoyl)indole (IN4) 
 
 
(S)-2-(Aminoisobutyl)-3-(N-4-chlorobenzylcarbamoyl)indole (IN4) was obtained as 
described in 6.2.2.12. Purification by silica gel chromatography MeOH (3 %) in DCM. 
Yield: 76 %; Dark green oil; MeOH (3 %) in DCM; Rf = 0.26, C20H22ClN3O, MW: 355.87 
g/mol; purity: 93 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 356 m/z. 
1H-NMR (400 MHz, CDCl3) δ 0.97 (d, 3H), 1.10 (d, 3H), 1.22-1.15 (m, 1H), 4.73 (d, 1H), 
5.26 (dd, 2H), 7.13-7.10 (m, 2H), 7.21-7.16 (m, 2H), 7.61-7.39 (m, 3H), 7.77 (d, 1H). 
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(S)-2-(Aminoisobutyl)-3-(N-3-fluorobenzylcarbamoyl)indole (IN5) 
 
 
(S)-2-(Aminoisobutyl)-3-(N-3-fluorobenzylcarbamoyl)indole (IN5) was obtained as described 
in 6.2.2.12. Purification by silica gel chromatography MeOH (3.5 %) in DCM. 
Yield: 26 %; Dark brown oil; MeOH (3.5 %) in DCM; Rf = 0.32, C20H22FN3O, MW: 339.41 
g/mol; purity: 96 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 340 m/z. 
 
(S)-2-(Aminoisobutyl)-3-(N-2,4-dichlorobenzylcarbamoyl)indole (IN6) 
 
 
(S)-2-(Aminoisobutyl)-3-(N-2,4-dichlorobenzylcarbamoyl)indole (IN6) was obtained as 
described in 6.2.2.12. Purification by silica gel chromatography MeOH (4 %) in DCM. 
Yield: 77 %; Dark brown oil; MeOH (4 %) in DCM; Rf = 0.26, C20H21Cl2N3O, MW: 390.31 
g/mol; purity: 95 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 391 m/z. 
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(S)-2-(Aminoisobutyl)-3-(N-3,5-difluorobenzylcarbamoyl)indole (IN7) 
 
 
(S)-2-(Aminoisobutyl)-3-(N-3,5-difluorobenzylcarbamoyl)indole (IN7) was obtained as 
described in 6.2.2.12. Purification by silica gel chromatography MeOH (4 %) in DCM. 
Yield: 74 %; Brown oil; MeOH (4 %) in DCM; Rf = 0.28, C20H21F2N3O, MW: 357.40 g/mol; 
purity: 89 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 358 m/z. 
 
6.2.2.13. General procedure for triazoles (TR1-TR8) 
Syntheses of triazoles were carried out as follows (Scheme 13): The first step was the 
protection of an α-amino acid (100 mg) with Boc. The conditions are described above in 
6.2.3. [113] Activation of (64) by Et3N (1.05 eq), ethyl chloroformate (ECF, 1.05 eq) in THF 
(at - 20 ºC. The Et3N·HCl formed during the reaction was filtered off), led to intermediate 
anhydrides (65) which were immediately reacted with NH2NH2·H2O (2 eq) in MeOH (5 mL) 
at 0 ºC and left to warm up to room temperature, to yield the hydrazides (66). The solvents 
were evaporated and EtOAc (8 mL) was added. The organic phase was washed with NaHCO3 
(sat) (3x) and NaCl (sat) (3x), dried over MgSO4 and concentrated to afford the N-protected 
amino acid hydrazides (66) in 75-90 % yield. Triazole formation (67) was carried out by 
stirring the hydrazides in ACN (6 mL) and DMF-DMA (1 eq) at 50 ºC for 1 h. A substituted 
amine (0.91 eq) was added in ACN (3 mL) and HOAc (10 eq). The temperature was increased 
from 50 to 120 ºC and the reaction mixture was left for 2.5 h, cooled, concentrated by 
evaporation of the solvents. The N-protected group was cleaved with a mixture composed of 
TFA/DCM/TIS/H2O (80:20:5:1) for 1 h to give the triazole compounds TR(1-8). Purification 
was carried out on silica gel eluting with DCM:MeOH (3-5 %). The compounds were 
obtained in 65-85 % yield.  
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Scheme 13: Reagents and conditions: a) 2.9 eq Et3N, 1.2 eq Boc2O, dioxane:H2O (1:1), r.t, 18 h. b) Et3N (1.05 
eq), ECF (1.05 eq), THF, 0 ºC, 1 h. c) NH2NH2·H2O (2 eq), MeOH, 0 ºC to r.t. d) i) DMF-DMA (1 eq), ACN, 50 
ºC, 1 h. ii) Substituted amine (0.91 eq), ACN, HOAc (10 eq), 120 ºC, 2.5 h. f) Deprotection conditions: 
TFA/DCM/TIS/H2O (80:20:5:1). 
 
6.2.2.13.1. Triazole analogues 
(S)-3-(Aminoisobutyl)-4H-(3-chlorobenzyl)triazole (TR1) 
 
 
(S)-3-(Aminoisobutyl)-4H-(3-chlorobenzyl)triazole (TR1) was synthesized as it was 
described in 6.2.2.13. Purification by silica gel chromatography MeOH (2 %) in DCM. 
Yield: 65 %; Grey oil; MeOH (2 %) in MeOH, Rf = 0.38, C13H17ClN4, MW: 264.76 g/mol 
Purity: 97 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 265 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.81 (d, 3H), 0.94 (d, 3H), 1.63-1.47 (m, 1H), 4.33 (d, 1H), 
5.46 (dd, 2H), 7.11 (d, 1H), 7.25 (d, 1H), 7.41 (dd, 2H), 8.79 (s, 1H). 
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(S)-3-(Aminobutyl)-4H-(3-chlorobenzyl)triazole (TR2) 
 
 
(S)-3-(Aminobutyl)-4H-(3-chlorobenzyl)triazole (TR2) was synthesized as it was described in 
6.2.2.13. Purification by silica gel chromatography MeOH (2 %) in DCM. 
Yield: 87 %; Pale gray oil; MeOH (2 %) in DCM Rf = 0.18, C13H17ClN4, MW: 264.76 g/mol 
Purity: 97 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 265 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.75 (t, 3H), 0.89-0.85 (m, 2H), 1.87 (dt, 2H), 4.74 (t, 1H), 
5.29 (dd, 2H), 7.13 (d, 1H), 7.20 (d, 1H), 7.37 (dd, 2H), 8.48 (s, 1H). 
 
(S)-3-(Aminobutyl)-4H-(3-fluorobenzyl)triazole (TR3) 
 
 
 
(S)-3-(Aminobutyl)-4H-(3-fluorobenzyl)triazole (TR3) was synthesized as it was described in 
6.2.2.13. Purification by silica gel chromatography MeOH (2 %) in DCM. 
Yield: 88 %; Gray oil; MeOH (2 %) in DCM Rf = 0.22, C13H17FN4, MW: 264.76 g/mol 
Purity: 98 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 265 m/z. 
1H-NMR (400 MHz, CDCl3) δ 0.66 (t, 3H), 0.87-0.84 (m, 2H), 1.79 (dt, 2H), 4.71 (t, 1H), 
5.31 (dd, 2H), 7.11 (d, 1H), 7.18 (d, 1H), 7.29 (dd, 2H), 8.51 (s, 1H). 
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(S)-3-(Aminomethylthiopropyl)-4H-(3-chlorobenzyl)triazole (TR4) 
 
  
(S)-3-(Aminomethylthiopropyl)-4H-(3-fluorobenzyl)triazole (TR4) was synthesized as it was 
described in 6.2.2.13. Purification by silica gel chromatography MeOH (3.5 %) in DCM. 
Yield: 89 %; Gray oil; MeOH (3.5 %) in DCM Rf = 0.26, C13H17ClN4, MW: 296.82 g/mol 
Purity: 94 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 297 m/z. 
1H-NMR (400 MHz, CDCl3) δ 0.78 (s, 3H), 0.88 (t, 2H), 1.83 (dt, 2H), 4.79 (t, 1H), 5.46 (dd, 
2H), 7.09 (d, 1H), 7.15 (d, 1H), 7.32 (dd, 2H), 8.46 (s, 1H). 
 
(S)-3-(Aminoisopentyl)-4H-(3-fluorobenzyl)triazole (TR5) 
 
 
(S)-3-(Aminoisopentyl)-4H-(3-fluorobenzyl)triazole (TR5) was synthesized as it was 
described in 6.2.2.13. Purification by silica gel chromatography MeOH (2 %) in DCM. 
Yield: 71 %; Pale gray oil; MeOH (2 %) in DCM Rf = 0.33, C14H19FN4, MW: 262.33 g/mol 
Purity: 95 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 293 m/z.  
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(S)-3-(Aminoisobutyl)-4H-(benzyl)triazole (TR6) 
 
  
(S)-3-(Aminoisobutyl)-4H-(benzyl)triazole (TR6) was synthesized as it was described in 
6.2.2.13. Purification by silica gel chromatography MeOH (2 %) in DCM. 
Yield: 54 %; Pale gray oil; MeOH (2 %) in DCM Rf = 0.17, C13H18N4, MW: 230.32 g/mol 
Purity: 93 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 231 m/z.  
1H-NMR (400 MHz, CDCl3) δ 0.87 (d, 3H), 0.93 (d, 3H), 1.66-1.44 (m, 1H), 4.41 (d, 1H), 
5.41 (dd, 2H), 7.16 (d, 1H), 7.32 (d, 2H), 7.48 (dd, 2H), 8.81 (s, 1H). 
 
(S)-3-(Aminoisobutyl)-4H-(4-chlorobenzyl)triazole (TR7) 
 
 
(S)-3-(Aminoisobutyl)-4H-(4-chlorobenzyl)triazole (TR7) was synthesized as it was 
described in 6.2.2.13. Purification by silica gel chromatography MeOH (2.5 %) in DCM. 
Yield: 77 %; Gray oil; MeOH (2.5 %) in DCM Rf = 0.26, C13H17ClN4, MW: 264.76 g/mol 
Purity: 97 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 265 m/z.  
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(S)-3-(Aminoethyl)-4H-(4-fluorobenzyl)triazole (TR8) 
 
 
(S)-3-(Aminoethyl)-4H-(4-fluorobenzyl)triazole (TR8) was synthesized as it was described in 
6.2.2.13. Purification by silica gel chromatography MeOH (2.5 %) in DCM. 
Yield: 85 %; Pale gray oil; MeOH (2.5 %) in DCM Rf = 0.23, C11H13FN4, MW: 220.25 
g/mol. Purity: 96 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 221 m/z.  
 
6.2.2.14. Synthesis of tert-butyl (4S)-2-bromo-4-((tert-butoxycarbonyl)amino)-5-methyl-
3-oxohexanoate (75) 
 
 
 
The starting reagent (54) (200 mg, 1 eq, 0.63 mmol) was brominated with N-
bromosuccinimide (90.3 mg, 0.8 eq, 0.5 mmol) in a solution of 2,6-lutidine (7.5 μL, 10 mol 
%, 0.063 mmol) in MeOH (7 mL) and stirred for 2.5 h at room temperature. Then, the 
solution was cooled at -20 ºC for 20 h. The reaction mixture was extracted with 50 % 
saturated NaCl (3x) and saturated NaCl (3x), dried over Na2SO4 and the solvents were 
evaporated to give the 2-bromo-β-ketone ester as crude product (75). It was purified by silica 
gel chromatography with cyclohexane:EtOAc (4:1) as eluents and obtained in yield 77 %. The 
core intermediate (75) was used for the synthesis of compounds ImPn1 and ImPm1. 
Rf = 0.21, C16H28BrNO5, MW: 393.12 g/mol. Purity: 89 % (HPLC-ESI-MS, 214 nm), 
[M+H]+ = 394 m/z. 
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6.2.2.15. Synthesis of (S)-2-(Aminoisobutyl)-3-(carboxylic acid)imidazo[1,2-a]pyridine 
(ImPn1) 
 
 
 
Compound (75) (95 mg, 1 eq, 0.24 mmol) was dissolved in EtOH (10 mL). 2-Aminopyridine 
(18.2 mg, 0.8 eq, 0.2 mmol) and NaHCO3 (13.2 mg, 0.65 eq, 0.15 mmol) were added and the 
solution was stirred for 12 h at room temperature. The solution was evaporated in vacuo and 
destilled water (5 mL) was added to the residue and extracted twice with CHCl3. This solution 
was washed with brine (2x) and dried over Na2SO4. The filtrate (76) was evaporated in vacuo. 
Cleavage of Boc protecting group was carried out with a mixture of TFA/DCM/TIS/H2O 
(85/20/5/1) to give the crude product ImPn1. The compound was purified by silica gel 
chromatography using MeOH (4 %) in DCM as eluents. 
Yield: 54 %; Rf = 0.26, C12H15N3O2, MW = 233.12 g/mol 
Purity: 73 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 234 m/z.  
 
 6.2.2.16. Synthesis of (S)-2-(Aminoisobutyl)-3-(carboxylic acid)imidazo[1,2-
a]pyrimidine (ImPm1) 
 
 
 
Compound (75) (90 mg, 1 eq, 0.22 mmol) was dissolved in EtOH (10 mL). 2-
aminopyrimidine (17.4 mg, 0.8 eq, 0.18 mmol) and NaHCO3 (12.5 mg, 0.65 eq, 0.14 mmol) 
were added and the solution was stirred for 12 h at room temperature. The solution was 
evaporated in vacuo and deionized water (5 mL) was added to the residue and extracted twice 
with CHCl3. This solution was washed with brine (2x) and dried over Na2SO4. The filtrate 
  
 
 
138 
(77) was evaporated in vacuo. Cleavage of Boc protecting group was carried out with a 
mixture of TFA/DCM/TIS/H2O (85/20/5/1) to give the crude product ImPm1. The compound 
was purified by silica gel chromatography using MeOH (4 %) in DCM as eluent. 
Yield: 56 %; Rf = 0.28, C11H14N4O2, MW: 234.26 g/mol 
Purity: 61 % (HPLC-ESI-MS, 214 nm), [M+H]+ = 235 m/z.  
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6.3. Antifungal screenings 
6.3.1. Materials 
6.3.1.1. Reagents 
All reagents used were of the maximum purity available. 
Reagent  Supplier 
RPMI medium  Invitrogen 
FBS (fetal bovine serum) Lonza 
YPD medium  Home made 
Propidium Iodide (PI)       --- 
DHR (dihydrorhodamine) Sigma Aldrich 
Tris-HCl Invitrogen  
EDTA (Ethylenediaminetetraacetate acid) Panreac 
NaCl Panreac 
DTT (dithiothreitol) AppliChem 
Phosphate-buffered saline (PBS)  Thermo Scientific 
phenylmethane sulfonyl fluoride (PMSF) Sigma Aldrich 
Protease Inhibitors Thermo Scientific 
Coomassie Blue staining Biorad 
Tetramethylethylenediamine (TEMED) Sigma Aldrich 
Sodium dodecyl sulfate (SDS) Duchefa Biochemie 
Ammonium persulfate (APS) Amersham Bioscience 
Acrylamide-Bis-Acrylamide Panreac 
β-Mercaptoethanol Sigma Aldrich 
Bromophenol blue Panreac 
YP (Yeast peptone) VWR international 
FDA (Fluorescein diacetate)         --- 
 
6.3.1.2. Instruments 
Instrument Supplier and Model 
Centrifuge Eppendorf 5810R 
Sonicator P-selecta 
Spectrometer Beckman DU 640 
Bead beater Millipore 
Incubator Infors HT 
Fluoresence microscope Nikon MicroscopyU 
Microlayout machine Victor3 
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6.3.2. Methods 
6.3.2.1. Primary high-throughput screening 
For HeLa cell culture, the following medium was used: RPMI 1640 medium with 10 % 
heat inactivated fetal calf serum (FCS), 2 mM L-glutamine and penicillin/streptomycin 
(P/S). 
Remarks: FCS is a common additive in most cell cultures and provides growth factors, 
hormones and other essential nutrients. Heat inactivation consists of heating the serum at 
56 ºC for 30 min to destroy components of the complement system. L-Glutamine tends to 
degrade in the medium; therefore it is always supplemented with some fresh extra L-
glutamine when opening a new bottle of medium. P/S is another common additive used 
routinely in cell culture, to prevent microbial infections. For this assay, HeLa cells were 
cultivated initially with P/S, and medium without P/S was used when the test compounds 
were added, to avoid any interference. 
- Medium preparation: 
FBS was thawed in a warm water bath, homogenizing the solution from time to time 
by gently inverting the tube. P/S and L-glutamine were also thawed but at room 
temperature.  
From a 500 ml RPMI 1640 medium bottle, 60 ml were removed (which could be 
discarded or saved for posterior use) and 50 ml of PBS as added. Then, 5 ml of P/S 
and 5 ml o fL-glutamine were added. 
- Splitting the cells (passaging): 
Splitting the cells, in case of HeLa and other adherent cell lines (cells that attach to the 
bottom of the flask), means detaching them from the bottom of the flask. The protocol 
followed was: addition of trypsin, accutase, collagenase or other enzymatic/non-
enzymatic agent, diluting and transferring them to a larger flask.  
Before to start the procedure it was necessary to inspect the flask visually to make sure 
it was not contaminated meaning that the medium should not be cloudy. Also, the 
confluency was checked under the microscope, to be almost 100 % confluent.  
The medium was aspirated from the flask with disposable glass pipette; the flask was 
washed with 10 ml PBS (37 ºC or room temperature) and the PBS aspirated. Addition 
then of 1 ml of one-time trypsin solution as cell detaching agent. After making sure 
that the whole surface of the flask was covered by trypsin solution, the flask was put 
back in the incubator and checked it after 10 min. To help to detach the cells, the flask 
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was shacked by tapping gently at the side of the flask. The flask was put into the 
incubator at 37 ºC to assure all cells were detached.  
Afterwards, 5 ml of media was added to stop the trypsinization and the cells were 
moved up and down a few times with pipette to dissolve clumps of cells. 500 μl of that 
cell suspension was transferred to an Eppendorf tube and the cells were counted. 
Then, the required volume of cell suspension was transferred to a new flask (1 million 
cells); the volume was completed up to 10 ml with medium, gently homogenized and 
put it in the incubator at 37 ºC. 
- Counting the cells with CASY: 
o 10 ml of CASY ton buffer was added to a disposable counting vial. 
o 100 μl of cell suspension was added to the vial, mixed by inverting 3 times.  
o The vial then was placed under the capillary and “start” bottom was pressed. In 
the current settings of that equipment, the value given was the number of cells 
per ml. If the sample was too concentrated, only 50 μl of cell suspension was 
used. 
- Preparation of stock solutions 
As the compounds to be tested were already weighed and stored into Eppendorf tubes, 
the diluent required to obtain a standard solution was calculated for a final 10 μM 
concentration. 
The compounds were diluted in DMSO into the calculated volume to obtain the 
desired stock solution.  
- Preparation of working solution 
From the stock solution, the calculated amount necessary to obtain a final 
concentration of 20 μM was pipetted.  
From that working solution, 20 μl were pipetted and transferred to the well-plate. 
 
- First day of assay: 
The assay was performed in a 96- well tissue culture plate, with a total volume of 200 
μl per well (50 μl of cells solution + 50 μl of fungus solution + 100 μl of screening 
compound solution). The procedure was simply to add all the components (cell + 
fungus + drug) to the well and then incubated the plate for 5 days at 37 ºC in a 5 % 
CO2 humidified incubator (standard cell culture condition).  
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In addition to all test compounds, three controls were necessary in this assay: cell 
viability control, fungus control and drug control. The cell viability control contained 
only HeLa cells; the fungus control contained HeLa cells + fungus, but no drug and 
the drug control contained HeLa cells + fungus + the drug amphotericin B.  
Everything was done in RPMI 10 % FC and 1 % L-glutamine (no antibiotics) 
•  HeLa cells: 10.000 cells per well (50 μl of a 200.000 cells /ml suspension 
• Test compound: 50 μM (100 μl of a 100 μM stock solution  
• Fungi: 50 CFU per well (50 μl of a 1000 CFU/ml suspension) 
• Drug control: amphotericin B at 1 μg/ml (100 μl of a 2 μg/ml stock solution) 
 
Layout of the 96 well-plate: 
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- Read-out of the plate (after 5 days) 
To assess the reading of cell viability, a spectrofluorometer was used and the dye 
fluorescein diacetate (FDA) excitation and emission wave-length was: 485 nm, and 
538 nm, respectively. 
FDA stock solution was diluted in DMSO to a concentration of 10 mg/ml. 
Afterwards, the FDA working solution was diluted in PBS: 1:1000 dilutions from the 
stock. 
The cells were washed with PBS (2x 100 μl), 100 μl of FDA working solution was 
added per well and the reading was performed.  
 
6.3.2.2. Dose-Response assay 
This assay followed exactly the same protocol as the highthrough put screening. The 
difference in this case, was that instead of working with only one concentration, a range of 
concentrations was done from 250 to 0.1953 μM. 
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6.3.2.3. Minimum inhibitory concentration (MIC) 
- Preparation of medium YPD 
For a liter of medium 25 g Bacto TM Peptone and 12.5 g Bacto TM Yeast Extract were 
dissolved in 800 ml of distilled water. The total volume was adjusted to 900 ml once 
all the components were completely dissolved. The YP solution was then autoclaved 
immediately and all the following steps were performed in a sterile workspace. To 900 
ml of YP solution 100 ml of 20 % glucose solution was added to obtain a final 
concentration of 2 % glucose. 
- Preparation of stock solutions 
The solution required to obtain a standard solution was calculated for two plates and 
for a concentration of 12.8 g/ml for peptides and 1.6 mg/ml for the heterocyclic 
compounds.  
The compounds to screen were dissolved with deionized water for peptides and with 
DMSO for heterocyclic compounds into the calculated volume to obtain the desired 
stock solution. The stock solutions were stored at -80 ºC until usage.  
- Preparation of working solutions 
The concentrations used in the adapted assay were based on the concentrations that 
were currently used for other azole antifungals (EUCAST protocol). The test range 
was 64 to 0.125 μg/ml for peptides and 10 to 0.0195 μg/ml for heterocyclic 
compounds. 
10 Falcon tubes were used to prepare the work solutions. The tube number one (D1, 
Table 35) was prepared by pippeting 36 μl from the stock solution and diluted with 
3564 μl of YPD medium to obtain a final volume of 3600 μl and therefore, a 
concentration of 128 μg/ml. The falcon tubes, 2-10, were prepared by pipetting 1800 
μl from the previous falcon tube into a new one with 1800 μl of YPD medium to get 
the final volume of 3600 μl (Table 36). 
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Table 36. Calculation of the final concentration for each falcon tube.  
Falcon nº 
Tube 
μl transferred to 
falcon 
Final concentration in 
the falcon tube 
Total Volume (μl) 
D1 36 128 3600 
D2 1800 64 3600 
D3 1800 32 3600 
D4 1800 16 3600 
D5 1800 8 3600 
D6 1800 4 3600 
D7 1800 2 3600 
D8 1800 1 3600 
D9 1800 0.5 3600 
D10 1800 0.125 3600 
  
- Colony suspension 
The inocolum was prepared by harvesting a single colony form an YPD-agar plate. 
The cells were transferred to an Eppendorf tube with 1 ml of sterile distilled water. 
The OD600 was measured on a photometer and adjusted with YPD medium to an 
OD600 of 0,01. In C. glabrata, this OD600 correlates to a cell density of 2.5 x 106 CFU 
per ml. 
- Inoculation of the plates 
For the assay, sterile 96 well microdilution plates with flat bottom and a capacity of 
200 μl were used. 100 μl of the antifungal dilutions were pipetted to the first ten 
columns of the 96 well plates (Table 36). The preparation mixture with the highest 
concentration was placed in column 1 while that with the lowest concentration was 
placed in column 10. Each well in column 11 was filled with 100 μl of YPD medium 
as a positive control and column 12 served as negative control with 200 μl of YPD 
medium. The whole plate layout is shown in Table 37. 
Afterwards, 100 μl of cell suspension were added to the wells in columns 1 to 11. For 
each strain two rows were used as duplicates. The plates were then incubated for 24 h 
at 30 ºC without agitation. As further positive control, two plates were filled only with 
YPD medium. 
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Table 37: Scheme of the plate layout. Green: solutions. Yellow: 100 % growth drug free. Orange 0 % growth 
(no inoculation). 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 100 0 
B D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 % % 
C D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 C C 
D D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 T T 
E D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 R R 
F D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 L L 
G D1 D2 D3 D4 D5 D6 D7 D8 D9 D10   
H D1 D2 D3 D4 D5 D6 D7 D8 D9 D10   
 
- Reading of the plates 
After incubating the plates for 24 h at 30 ºC, the OD600 values were measured using a 
plate reader (Victor3). Table 38 shows exemplary results for such measurement. 
 
Table 38: Scheme of the results obtained after OD600 measurement.   
 
 
6.3.2.4. Screening of clinical Candida spp isolates 
The screening plates with 100 µl of medium YPD were supplemented with 100 µl of the 
respective antifungal compound (all wells except the last 4 of the plates) with the 
concentration determinate based on the previous MICs assay.  
The clinical isolates were arrayed in a 96-well pattern on a solid media square plate. Using a 
Singer RoTor HDA robot, they were transferred to the 96-well plate holding the 200 µl (YPD 
media + peptide) and incubated at 30 °C for 24 h.  
The readings were carried out after those 24 h of incubation by measuring the OD600 at 
Victor3 plate reader.  
The empty wells containing only media was used as a blank for the growth.  
 
 
1 2 3 4 5 6 7 8 9 10 
SC5314 A 1,252 1,275 1,261 1,259 1,251 1,254 1,257 1,248 1,246 1,248 
SC5314 B 1,241 1,246 1,237 1,235 1,239 1,237 1,249 1,244 1,237 1,235 
ATCC2001 C 1,439 1,440 1,429 1,430 1,422 1,422 1,428 1,432 1,431 1,431 
ATCC2001 D 1,434 1,438 1,425 1,427 1,428 1,418 1,432 1,430 1,424 1,428 
ATCC22019 E 0,407 0,397 0,383 0,386 0,396 0,399 0,398 0,390 0,387 0,390 
ATCC22019 F 0,411 0,404 0,388 0,392 0,401 0,404 0,408 0,401 0,399 0,395 
ATCC6258 G 1,051 1,018 0,996 1,001 0,998 0,998 1,003 0,991 0,994 1,004 
ATCC6258 H 1,054 1,027 1,000 1,059 1,003 1,013 1,008 1,004 1,000 0,998 
µg.ml-1 64 32 16 8 4 2 1 0,5 0,25 0,125 
Relative growth 
1 2 3 4 5 6 7 8 9 10 
SC5314 A 99,7 101,7 100,4 100,3 99,6 99,9 100,1 99,3 99,2 99,4 
SC5314 B 100,3 100,8 100,0 99,8 100,2 100,0 101,0 100,6 100,0 99,8 
ATCC2001 C 100,6 100,6 99,8 99,9 99,3 99,3 99,7 100,0 99,9 99,9 
ATCC2001 D 100,2 100,5 99,6 99,7 99,7 99,0 100,1 99,9 99,5 99,7 
ATCC22019 E 104,4 101,3 96,3 97,5 100,9 101,9 101,6 98,8 97,9 99,0 
ATCC22019 F 103,6 101,0 95,8 97,4 100,1 101,2 102,6 100,2 99,7 98,1 
ATCC6258 G 106,2 102,5 100,0 100,6 100,3 100,2 100,8 99,5 99,8 100,9 
ATCC6258 H 106,1 103,1 100,3 106,8 100,5 101,6 101,0 100,6 100,2 100,0 
µg.ml-1 64 32 16 8 4 2 1 0,5 0,25 0,125 
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6.3.2.5. Proteomic assay 
6.3.2.5.1. Fluorescence microscopy 
A preinoculum culture of C. albicans SC5314 was cultivated overnight in YPD 
medium (50 ml) at 30 ºC and adjusted to an optical density (OD) of 0.4. 
To reveal the influence of EMC120B12 and BE10 on the proteomic level on C. 
albicans, 50 ml RPMI 1640 medium with 10 % FBS was inoculated with the 
preinoculum of C. albicans SC5314 and adjusted to an optical density (OD) of 0.4 and 
grown for 1.5 h, 3 h, 4.5 h and 6 h at 37 ºC with and without the compounds using 
their IC50 previously determined (0.75 µM and 0.194 µM, respectively). 
Therefore, 3 inoculations for each time corresponding to SC5314; SC5314 + 
EMC120B12 (0.75 µM) and SC5314 + BE10 (0.194 µM) (Scheme 14) were 
prepared. 
30 min before the time points, 1 ml of each culture was transferred to three laboratory 
tubes, which were treated as follows:  
o Lab tubes A: Addition of 60 µl H2O2 (30 %) to induce a positive control of 
oxidative stress with 25 µl DHR. 
o Lab tubes B: no addition. 
o Lab tubes C: Addition of 25 µl DHR. 
After the time points, the samples were transferred to Eppendorf-cups and centrifuged 
at 7000 rpm for 10 min discarding the medium.  
o To tub A: After centrifugation, the Eppendorf-cup contents were washed by 1 
ml of PBS (3x).  
o To tub B: After centrifugation, 1 ml of EtOH was added and kept at 4 ºC for 10 
min. After removing EtOH, 1 ml of PBS and 10 µl (100 µg/ml) of PI were 
added. The solutions were kept at room temperature for 5 min and later 
discarded and washed with PBS (3x).  
o To tub C: After centrifugation, 10 µl of PI was added and the mixture was kept 
at room temperature for 5 min. Later the tubs were washed with PBS (3x). 
This procedure was repeated three times. 
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Scheme 14: a) preinoculum culture of C. albicans SC5314 was prepared overnight at 30 °C and adjusted to an 
OD of 0.4. b) 50 ml of RMPI was inoculated with the compounds to study (EMC120B12 and BE10) with the 
preinoculum of C. albicans early prepared and left at 37 °C to the corresponding times (1.5; 3; 4.5 and 6 h). c) 
30 min before the time points, 1 ml of each culture was transferred to 3 laboratory tubes and they were treated as 
it is described. d) after the time points, the solutions were transferred to 3 Eppendorf-cups. 
 
These samples were examined using a fluorescence microscope at 596 nm for ROS+ and 617 
nm for PI. 
 
6.3.2.5.2. Protein extraction by cell lysis 
A preinoculum culture of C. albicans SC5314 was prepared in YPD medium (50 ml) 
at 30 ºC for 12 h and adjusted to an optical density (OD) of 0.4. 
To reveal the influence of EMC120B12 and BE10 on the proteomic level and on C. 
albicans, 50 ml RPMI 1640 medium with 10 % FBS was inoculated with the 
preinoculum of C. albicans SC5314 and adjusted to an optical density (OD) of 0.4 and 
grown for 1.5 h, 3 h, 4.5 h and 6 h at 37 ºC with and without the compounds using 
their IC50 previously studied (0.75 µM and 0.194 µM, respectively). 
Therefore, 3 inoculations for each time corresponding to SC5314; SC5314 + 
EMC120B12 (0.75 µM) and SC5314 + BE10 (0.194 µM) were prepared (Scheme 
15). 
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After time points of 3 and 4.5 h, the solutions were centrifuged at 4 ºC for 10 min 
(2500 rpm) and the supernatant was removed. The cells were washed with PBS (3x) 
and transferred to Eppendorf-cups.  After washing, the samples were resuspended in a 
lysis buffer composed by Tris-Hcl 50 mM (pH 7.5), 1 mM EDTA, 150 mM NaCl, 1 
mM DTT, 0.5 % PMSF and 1 % of proteinases inhibitor. 
To assure the rupture of the cells, glass beads were added and the samples were treated 
to 10 cycles of rupture in a bead beater. For each cycle of 20 s, the samples were 
cooled down for 2 min. After the lysate, the suspensions were centrifuged (2x) and the 
supernatant was recollected. 
 
 
Scheme 15: a) Preinoculum culture of C. albicans SC5314 was prepared at 30 °C for 12 h and adjusted to an OD 
of 0.4. b) 50 ml of RMPI was inoculated with the compounds to study (EMC120B12 and BE10) with the 
preinoculum of C. albicans early prepared and left at 37 °C to the corresponding times of 3 and 4.5 h. c) The 50 
ml were transferred to falcons and centrifuged. d) The supernatant was removed and the pellets were washed 
with PBS and transferred to Eppendorf-cups. e) After cell lysis, the proteins were quantified by Bradford 
quantification. f) To visualize the proteins, a SDS-PAGE gel was carried out for all samples and replicates.   
 
6.3.2.5.3. Protein quantification by Bradford method 
To prepare the standard curve, a BSA protein sample concentration was used: 
Eppendorf 1 2 3 4 5 6 7 Sample 
BSA (V) 
1 mg/ml 
0 µl 0.5 µl 1 µl 2 µl 4 µl 8 µl 16 µl 5 µl 
Protein 0 µl 1 µl 2 µl 4 µl 8 µl 16 µl 32 µl X 
Bradford 
reagent 
200 µl 200 µl 200 µl 200 µl 200 µl 200 µl 200 µl 200 µl 
H2O 800 µl 799.5 µl 799 µl 798 µl 796 µl 792 µl 784 µl 795 µl 
 
50 ml 
SC5314 
SC5314 + 
EMC120B12 
SC5314 
+ D-10 
a 
b 
c 
Bradford 
quantification 
Gel SDS-PAGE 
d e f 
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The Eppendorf-cups were incubated for 15 min in a dark box at room temperature. 
Then, the absorbances were measured at 595 nm and the regression line was made. 
To obtain the sample concentration, the following regression formula was applied:  
 
y = 0.0498x + 0.0144 
 
(X is the concentration and Y the absorbance). 
 
6.3.2.5.4. Protein visualization by SDS-PAGE gel 
 
➢ Gel preparation:  
 Stacking Gel (stock 50 ml) Resolving Gel 
H2O 31.25 ml 5 ml 
Tris-HCl (1.5 M pH 8.8) --- 2.5 ml 
Tris-HCl (1.5 M pH 6.8) 12.50 ml --- 
Acrylamide-bis-acrylamide 
Solution (40 %) 
6.25 ml 2.5 ml 
SDS (10 %) 250 µl 50 µl 
APS (10 %) for 10 ml 100 µl 100 µl 
TEMED (for 10 ml) 10 µl 10 µl 
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The resolving gel was prepared and immediately loaded in the integrated space of the 
glass plates. After addition of methanol to avoid polymerization inhibition, the plates 
were incubated for 30 min. Meanwhile, the stacking gel was prepared without the 
addition of TEMED and APS.  
Methanol was then removed and then TEMED and APS were added to the 
concentration gel and loaded to the plates. They were incubated for 30 min to allow 
the polymerization. 
The glass plate sandwiches were placed in the electrode assembly and the electrode 
assembly was filled with running buffer composed of 250 nM Tris-HCl, 1.92 M 
glycine and 1 % SDS.  
40 µg of each sample was dissolved in sample buffer consisting of 30 nM Tris-HCl pH 
6.8, 10 % SDS, 50 % glycerol, 3.5 M β-mercaptoethanol, bromophenol blue traces. 
The samples were heated at 100 °C for 10 min and later incubated on ice for further 10 
min. The samples were centrifuged at 13.000 rpm for 2 min and then loaded to the gel. 
Then, the electric source was started at 100 V and left running until the bromophenol 
blue reached the edge of the gels. 
The gels were extracted and dyed with bromophenol blue for 2-3 h and washed with 
methanol.  
 
6.3.2.5.5. Protein digestion 
After running the gel, some bands were cut out as closely as possible with a sharp 
scalpel and then cut into smaller pieces that were approximately 1 mm2 to 2 mm2. 
The bands were transferred to Eppendorfs and washed 2 times with 50 µl of ACN 
during 5 min. The samples were dried in the Speed-vac for 15 min. 
To reduce the samples, 50 µl of DTT solution (10 mM dithiothreitol) was added and 
incubated at 56 °C for 30 min.  
DTT was removed by pipetting and washed with 50 µl of ACN (100 %) for 5 min. It 
was important to have the samples well dried, therefore the samples were dried again 
in the Speed-vac for 30 – 45 min.  
To start the digestion, 1 µg of trypsin in 100 µl of Ambi 25 nM were added and 
incubated at 4 °C for 45 min.  
After removing the excess of trypsin that was not incorporated in the gel, 50 µl of 
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Ambi 25 mM was added and incubated this time at 37 °C overnight. 
On the next day, the samples were centrifuged for 1 min at 12.000 rpm. The peptide 
solutions in Ambi buffer were transferred to a fresh Eppendorf to extract the peptides 
as follows: 
- 30 µl of ACN was added for 5 min. Then, ACN was removed.  
- 20 µl of Ambi  + 20 µl of ACN were added for 5 min. Then, all the mixture was 
removed and transferred to a new Eppendorf. 
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